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ABSTRACT 
 
Bosny J Pierre-Louis: APPLICATION OF NOVEL STATISTICAL METHODS 
FOR BIOMARKER SELECTION TO HIV INFECTION DATA 
(Under the Direction of Drs. C.M. Suchindran and Pai-Lien Chen) 
 
The past decade has seen an explosion in the availability and use of biomarker data 
as a result of innovative discoveries and recent development of new biological and 
molecular techniques.  Biomarkers are essential for at least four key purposes in 
biomedical research and public health practice: they are used for disease detection, 
diagnosis, prognosis, to identify patients who are most likely to benefit from selected 
therapies, and to guide clinical decision making.  Determining the predictive and 
diagnostic value of these biomarkers, singly or in combination, is essential to their 
being used effectively, and this has spurred the development of new statistical 
methodologies to assess the relationship between biomarkers and clinical outcomes.  
One active area of research is the development of variable importance measures, a 
class of estimators that could reliably capture the effect of a specific biomarker on a 
clinical outcome.  The central question addressed in this dissertation is the 
following: Given a large set of biomarkers that potentially predict a clinical outcome, 
how can one make a determination as to which ones are the most important?  In the 
first paper, we estimate a targeted variable importance measure through Van der 
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Laan’s theory of targeted maximum likelihood estimation in the point treatment 
setting and use the same objective function to compute an alternative measure of 
marginal variable importance based on weights from a flexible propensity score 
model. Covariate-adjusted targeted variable importance measures are compared to 
estimates from this alternative methodology and to incremental value estimates 
from partial ROC curves.  In the second paper, we extend the applicability of the 
TMLE methodology to analyze longitudinal repeated measures data.  It addresses 
the gap caused by the absence of a generally accepted approach for generating a 
longitudinal variable importance index by proposing an estimator involving both 
TMLE and computation of the area under or above the LOESS curve.  A graphical 
method is proposed for visual assessment of the longevity of a biomarker in terms of 
its predictive power, information that could be used to determine when repeated 
measures of a biomarker should be taken.   Finally, in the third paper we take right 
censoring in the outcome variable into consideration and achieve biomarker 
selection in the presence of confounding and potential informative censoring 
through the use of stabilized weights in a time-dependent Cox proportional hazards 
model.  A dataset from the Hormonal Contraception and HIV Genital Shedding and 
Disease Progression Study that includes longitudinal HIV infection data on a sample 
of 306 HIV-infected adult women from Uganda and Zimbabwe was used to develop 
and evaluate the methods discussed in the three papers.  This study collected 
information on a number of biomarkers related to HIV infection, including plasma 
viral load, HIV subtype, CD4 and CD8 lymphocyte counts, hemoglobin level, and 
herpes simplex virus 2 (HSV-2).  The relationships of these biomarkers with changes 
in CD4 cell counts were considered in three different contexts: cross-sectional, 
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longitudinal and survival.  In short, baseline CD4 cell counts, HIV subtype, and 
HSV-2 were found to be important biomarkers for the outcome variable studied. 
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CHAPTER I 
1. Introduction/Background 
Fueled by recent advances in modern biology and technology, biomarkers have 
become a popular research topic in clinical investigations.  As biological tools that 
can be used to monitor the presence or absence of disease, disease progression, the 
effect of a treatment, and the toxicity of a drug, biomarkers are important to the 
pharmaceutical industry, to federal regulatory agencies such as the Food and Drug 
Administration (FDA), and to public health researchers. In the pharmaceutical 
industry, the growing need for biomarker data collection stems from, among many 
benefits, their usefulness in driving decision-making, particularly at early phases of 
clinical trials.  By facilitating the identification of positive responders and non-
responders to therapeutics, biomarkers have provided an impetus for the 
development of targeted therapies and personalized medicines.  By the same token, 
they have the potential to improve the late phase trial success rate through better 
decision making earlier in the process of drug development.  This targeted strategy 
has the potential to improve efficiency in the drug development process while at the 
same time maximizing patient safety and efficacy.   
Another practical advantage of biomarkers is that they have the ability to reduce 
the need for hard clinical endpoints.  Overall, biomarkers lend themselves to earlier 
and easier measurements than clinical outcomes, are less subject to competing risks, 
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and can reduce clinical trials sample size requirements.  In pharmaceutical research, 
this could translate into more cost-effective trials, shorter study duration, improved 
compliance, and the opportunity to bring new therapies to the market more quickly. 
In the public health arena, biomarker data can be used to measure the prevalence of 
certain health conditions, to identify disease risk factors, and to evaluate the impact 
of interventions.  They could play a pivotal role in disease prevention efforts by 
providing ways to detect diseases in the preclinical stage when it may be possible to 
achieve a positive reversal in the outcome.  In vaccine trials, biomarkers reduce 
reliance on costly and lengthy efficacy studies by facilitating identification of 
serologic tests that predict protection from given conditions or by making possible 
earlier assessment of the safety and efficacy of candidate vaccines (Hogrefe, 2005).  
The numerous benefits of biomarkers in clinical research explain why the watershed 
FDA–National Institutes of Health (NIH) consensus conference biomarkers held in 
1999, the 2006 FDA Critical Path Initiative, the European Medicines Agency 
(EMEA) Road Map to 2010, and various stakeholders from the pharmaceutical 
industry and from patient advocacy groups, have all called for a key role of 
biomarkers in the drug development process.  Collaborative efforts to advance 
biomarkers research are exemplified by the work of the Biomarkers Consortium 
(http://www.biomarkersconsortium.org), a public-private partnership, launched in 
2006 with the goal to "identify and qualify new biological markers to speed the 
detection, diagnosis, and treatment of disease‖ and by the innovative approach to 
cancer biomarker development taken by the National Cancer Institute’s Early 
Detection Research Network (http://edrn.nci.nih.gov/). 
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In spite of the popularity of biomarkers, their vast spectrum of uses and 
utility, and the ever-increasing availability of biomarker data, there are still concerns 
about either a lack of progress in biomarker discovery or a gap between the pace of 
biomarker discovery and the development of novel statistical methods to evaluate 
their different performance characteristics.  Such factors could serve as an 
impediment to effective treatment/cure for diseases such as diabetes, obesity, 
endocrine, digestive, and metabolic conditions, among others.  The prerequisite for 
clinical use of biomarkers in the diagnosis, treatment, and prognosis of these 
conditions is an adequate biomarker discovery process.  Key statistical questions 
asked during this process are whether the candidate biomarkers reliably predict the 
outcome of interest, whether the observed association between candidates and 
outcome is not confounded by extraneous factors, and which candidates display the 
best performance characteristics.  Answers to these questions require the 
development and application of novel statistical methods for biomarker selection 
and validation.  
In this dissertation, the research question is how to quantify the impact of a 
biomarker on a given outcome (e.g. CD4 cell count) and use this measure of impact 
as a tool for ranking biomarkers.  Answers to this question are of great practical 
importance to public health.  By allowing researchers to take a pool of biomarkers 
and make a reliable determination of which ones are the most important, such 
measures could lead to faster decision making in epidemiologic studies and clinical 
trials.  For instance, an effective and efficient selection of the best subset of 
biomarker amongst a set could help direct further biological research in early phases 
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of clinical trials by limiting the focus to the pool of most promising ones only.  From 
a scientific standpoint, this could guide statistical research in the area of biomarker 
validation by making available a list of good candidates for surrogacy status 
determination.  Such a list could also be useful in the quest for the best combinations 
of biomarkers. 
1.1. Critical Evaluation of Existing Knowledge 
1.1.1. Biomarker and HIV Review 
According to the Biomarkers Definition Working Group, a task force convened by 
the National Institutes of Health (NIH), a biomarker is defined as a characteristic 
that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention (Clinical Pharmacology and Therapeutics 2001, 69: 89–95).  This broad 
definition encompasses all diagnostic tests, imaging technologies, and any other 
objective measures of a person’s health status (Desai et al, 2006).  Despite the fact 
that over the past decade biomarkers have been a driving force behind medical 
practice innovation,  concerns over the availability of sound and effective statistical 
methods necessary to evaluate  their characteristics have impeded their efficient 
application (Lasserre et al, 2007).  Given that biomarker data can be used for disease 
detection, diagnosis, prognosis, or for identification of patients who are most likely 
to benefit from selected therapies (Alaiya et al, 2005), advances in biomarker 
discovery could pave the way towards a predictive, preventative, and personalized 
approach to medicine (Weston and Hood, 2004).  Thus, it is imperative to develop 
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improved statistical methods that can help harness the vast potential of biomarkers 
in clinical practice.  
A biomarker that is intended to substitute for a clinical endpoint is a surrogate 
endpoint. Temple (1995) defines a surrogate endpoint as a laboratory measurement 
or a physical sign used as a substitute for a clinically meaningful endpoint that 
measures directly how a patient feels, functions or survives.  Changes induced by a 
therapy on a surrogate endpoint are expected to reflect changes in a clinically 
meaningful endpoint.   
The process of conferring surrogacy status to a biomarker entails a rigorous 
qualification process.  One element of this process is statistical validation. The goal, 
in validating surrogate markers, is to establish that they can reliably predict clinical 
benefit, harm, or futility of a new therapy. A qualification process map for the 
purpose of classifying biomarkers as exploratory, probable valid, or known valid has 
been established by the FDA (Goodsaid and Frueh, 2007). 
Prentice (1989) was the first to provide a statistical definition of surrogacy.  
According to this operational definition, a surrogate marker is a response variable 
for which the conditional distribution of the outcome given the surrogate marker 
alone is the same as the conditional distribution of the clinical outcome given the 
surrogate marker and the treatment.  Borrowing notation from Molenberghs and 
colleagues (2009), let T and S be random variables denoting true and surrogate 
endpoints respectively, and let Z be an indicator variable for treatment. To establish 
Prentice’s criterion, the following conditions are necessary (Molenberghs et al., 
2009): 
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1. Treatment Z has a significant impact on the surrogate endpoint S. 
2. Treatment Z has a significant impact on the true endpoint T. 
3. The surrogate endpoint S has a significant impact on the true endpoint T. 
4. The surrogate endpoint S captures the entire effect of the treatment Z upon 
the true endpoint T. 
The current consensus in statistical literature is that Prentice’s criteria are neither 
sufficient nor necessary and are difficult to achieve (Molenberghs et al., 2004, 2009; 
Qu and Case, 2006).  Also, a serious drawback of Prentice’s criterion, identified by 
Frangakis and Rubin (2002) is its lack of causal interpretation.  Prentice’s criterion 
reflects net effects, a combination of the causal effect of a treatment and systematic 
differences between compared groups arising from possible selection bias.  
Frangakis and Rubin (2002) proposed instead a surrogate validation model based on 
counterfactuals.  They introduced a new definition of surrogate endpoint, the 
―principal surrogate‖ based on principal stratification and principal effects.  In this 
framework, principal effects with respect to a post-treatment variable (e.g. 
biomarker) are evaluated within principal strata defined as ―cross-classification of 
subjects defined by the joint potential values of that post-treatment variable under 
each of the treatments being compared‖ (Frangakis and Rubin, 2002).  Principal 
strata are not affected by treatment and, therefore, play a role akin to baseline 
covariates.  Comparisons within principal strata yield causal interpretations as these 
comparisons are made between comparable groups of subjects. 
Using the principal stratification proposed by Frangakis and Rubin, Gilbert and 
Hudgens (2008) introduced an estimand for evaluating a principal surrogate, the 
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―causal effect predictiveness surface‖. This quantity measures how well causal 
treatment effects of the biomarker predict causal treatment effects of the clinical 
endpoint (Gilbert and Hudgens, 2008).  
For an exhaustive review of statistical approaches to biomarker validation, see 
Weir and Walley (2006), Lasserre (2007), Buyse et al (1998, 2000), Molenberghs et 
al. (2009), Frangakis and Rubin (2002). Biomarker validation is beyond the scope of 
this research. 
In spite of their advantages, biomarkers do have limitations that warrant a 
cautionary note.  They can be prone to measurement errors, storage problems, high 
costs of measurements, and can be fraught with ethical issues (Mayeux, 2004).  
Extreme caution should be exercised when biomarkers are used to replace true 
clinical endpoints.  According to existing literature, earlier attempts to use 
biomarkers as surrogates have led to some flawed and sometimes harmful 
conclusions (Fleming and Demets, 1996).  A well publicized failed attempt to use 
surrogate endpoints has been the FDA approval of the drugs encainide, flecainide, 
and moricizine, predicated on the notion that arrhythmia suppression by these drugs 
would lead to overall survival.  The use of electrocardiographic findings as surrogates 
for sudden death was subsequently undercut by the Cardiac Arrhythmia Suppression 
Trial (CAST) that found higher mortality and non fatal cardiac arrest events in 
patients taking these drugs as compared to placebo (NEJM, 1989, 321:406-12; Echt 
et al., 1991). 
Notwithstanding these concerns, biomarkers continue to play an increasingly 
important role in drug development.  As a driving force for pharmaceutical 
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innovation and personalized medicine (pharmacogenomics), biomarkers have the 
potential to lead to faster decision making since they can lend themselves to earlier 
and easier measurements than related clinical outcomes and could be less subject to 
competing risks.  This could translate into more cost-effective trials, shorter drug 
study duration, improved compliance, and the opportunity to bring new therapies to 
the market more quickly, as evidenced by the benefits to the whole drug life cycle 
brought by the accelerated approval of the drug Herceptin (trastuzumab) by the FDA 
in 1998.  Manufactured by Genentech/Roche, this drug targets the 25-30% of breast 
cancer patients who have the genetic alteration of the human epidermal growth 
factor receptor2 protein HER2.  As a result of accelerated approval for this molecular 
targeted therapy, Roche saved an estimated $35 million in clinical trial costs, 
collected $2.5 billion of income, while 120,000 patients gained access to the drug 
earlier than they would normally do (Thomson Scientific White Paper, March 2008).  
Note that this drug has been approved together with a molecular diagnostic that 
could determine (based on the expression of genetic biomarker HER-2) whether a 
patient might benefit from the drug. 
An area of research where the use of biomarkers can foster innovative advances is 
HIV/AIDS - the focus for the application of statistical methods used in this research.  
In fact, based on existing regulation known as the subpart H Approval that allows the 
use of surrogate endpoints for serious or life-threatening illnesses, the FDA has used 
scientific evidence from biomarkers to grant approval for several anti-HIV drugs, 
including Didanosine, Nevirapine, Lopinavir, and Efavirenz (Desai et al, 2006).  
Over time, with the increasing complexity of HIV infection research and the quest for 
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a safe and effective treatment, the use of biomarkers related to HIV infection 
remains an active area of research.  In an article published in April 2009 in the 
Journal of Acquired Human deficiency Syndrome (JAIDS), MacLachlan et al. touted 
the multiple beneficial roles that biomarkers could play in HIV vaccines.  This paper 
emphasized how biomarkers such as the BED enzyme immunoassay (BED-EIA) and 
the nucleic acid amplification testing (NAAT) could be used to estimate prevalence 
and incidence of HIV, information that could then be used for the determination of 
sample size and study populations for HIV efficacy trials.  It also demonstrated how 
sexually transmitted infection (STI) biomarkers could be used to generate valuable 
information on HIV infectiousness, transmissibility, and disease progression 
(MacLachlan et al., 2009). 
  In HIV infection studies, HIV RNA copies and CD4 cell counts are biomarkers 
routinely used to assess response to treatment or to monitor the progression of 
disease (Ellenberg, 1991; Lagakos and Hoth, 1992; Machado et al., 1990; Fleming, 
1994; Chen et al., 2007; Brown et al., 2009).  As a measure of a patient’s immune 
capacity, CD4 cell count is considered as a standard method for determining 
eligibility for highly active antiretroviral therapy (HAART) and HIV disease 
progression. Using a cohort of 489 Kenyan pregnant women, Brown et al (2009) 
found that CD4 could be a useful predictor of mortality.  This is in line with prior 
conclusions from both individual studies (Kawado et al, 2006; Planella et al. 1998; 
Liotta et al. 2004) and meta-analysis (Cross Continents Collaboration for Kids 
(3Cs4kids) Analysis and Writing Committee, 2008).   However, it is not always 
possible to measure CD4 cell count, especially in resources-deprived settings.  Both 
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viral load and CD4 cell count measurements require highly skilled personnel and 
costly maintenance of sophisticated pieces of equipment.   These costs can be 
prohibitive in resource-poor countries, thereby limiting access to these tests for 
those who need them the most.  A literature search reveals a few studies that 
examined the usefulness of less expensive biomarkers as potential surrogates for a 
CD4 cell count.  The results, however, have not always been conclusive.  Some 
studies have found HIV-1 RNA to be the best predictor of long term CD4 cell count 
responses and disease progression (Mellors et al., 1997; Fiscus et al., 1998).  Others 
have suggested that total lymphocyte count (TLC) is a good predictor of low CD4 cell 
counts (Montaner et al, 1992; Blatt et al. 1993; Martin et al, 1995; Shapiro et al., 
1998).  At least one study concludes that TLC is not a good predictor of CD4 cell 
count and, therefore, should not be used in the clinical care of HIV/AIDS patients 
(Van der Ryst et al., 1998). For a more complete list of references covering the 
relationship between TLC and CD4 cell count, see Chen et al (2007).  Overall, no 
studies have attempted to provide a single scalar measure of the marginal 
importance of biomarkers on CD4 cell count, to the best of our knowledge.  The 
closest attempt was made in Brown et al. (2009) who provided screening 
performance measures for several biomarkers separately.  However, the clinical 
outcome considered was mortality, and no attempt was made to generate and 
compare results from different statistical methodologies.  What is lacking is a unified 
list of biomarkers that can predict of CD4 cell counts based on sound statistical 
methodologies. This dissertation is intended to fill these gaps. 
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1.1.2. Review of statistical methods for biomarker selection 
A survey of statistical methods used for biomarker selection reveals that both 
standard and novel statistical methods have been employed to address the 
challenges of biomarker selection.  A non-exhaustive list of methods used to this end 
include univariate testing;  classical multivariable regression techniques such as 
ordinary least squares and logistic regression; the Receiver-Operating Characteristic 
(ROC) curve; non-linear models and machine learning techniques  such as 
classification and regression tree, Bagging, Boosting, random forest, and pattern 
recognition techniques; and marginal structural models for causal inference. We 
present a summary of some of these methods below. 
1.1.2.1. Univariable Screening 
In the univariate setting, a series of separate tests of the null hypothesis of no 
difference in the distribution of each biomarker across groups (e.g. diseased and no 
diseased) are performed, and screening is made based on the p-values associated 
with those tests.  For comparison of biomarkers measured on a continuous scale, t-
tests or variants thereof (Wilcoxon test, Welch test) are used (Dudoit el al., 2002; 
Guoan et al., 2002; Tusher et al., 2001; Cui and Churchill, 2003).  For binary 
biomarker variables, chi-square tests of Fischer exact tests are often conducted. 
From a modeling standpoint, simple linear regression is often used to model the 
relationship between the outcome and each biomarker separately.  In this setting, 
parameter estimation is done via the method of least squares.  Simple logistic 
regression is a common choice for binary outcomes.  The coefficient for each 
biomarker of interest is interpreted as its importance measure.  P-values, based on 
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univariate analysis of group mean differences for each biomarker are often adjusted 
for multiplicity (Tuglus, 2008).   
1.1.2.2. Multivariable Screening 
Multivariable screening, linear or non-linear, provides an analytical framework 
where all biomarkers can be evaluated simultaneously with or without covariate 
adjustment. Classical multivariable regression techniques such as ordinary least 
squares and logistic regression are two widely used linear models. An example of 
widely popular methods based on ordinary least squares estimation is the analysis of 
covariance (ANCOVA) where potential confounders are also included as predictors 
in a regression model (Cook and Campbell, 1979).  
In more recent developments, focus has been placed on non-linear models and 
machine learning techniques to improve biomarker prediction, classification and 
selection.  Among those, classification and regression tree (Breiman et al., 1984), 
Bagging (Breiman, 1996), Boosting (Freund and Schapire, 1997), random forest 
(Breiman, 2001 ), and pattern recognition techniques (such as support vector 
machines, neural networks and Markov models) (Vapnik, 1998; Burges ,1998)   have 
been successfully applied to high dimensional genomic and proteomic data (Wu et 
al., 2003; Qu et al., 2002).  In their 2003 paper, Wu et al. reviewed and compared 
the performance of several multivariate methods used for classification and selection 
of biomarkers.  These include both classical discriminant methods such as linear 
discriminant analysis, quadratic discriminant analysis, k-nearest neighbor classifier, 
as well as machine learning techniques like bagging and boosting classification trees, 
support vector machine and random forest.  Wu’s application of these techniques to 
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an ovarian cancer Mass spectrometry dataset has shown that, among all these 
methods, random forest has had better performance in terms of feature selection and 
sample classification. One remarkable advantage of random forest classifier is the 
fact that it reports an importance measure for each variable (VIM).  These VIM 
represent internal estimates of the decrease in the classifier’s overall accuracy if that 
particular variable was not used in building the classifier. In this regard, variables 
with larger importance measures can be deemed to have more classification power 
(Datta and Depadilla, 2006).  Tuglus et al (2008), however, outlines the following 
pitfalls associated with prediction algorithms such as random forest:  there is no 
guarantee that all biomarkers from a set will receive a measure of importance, there 
is no formal inference, and therefore, no p-values. Finally, variable importance 
measures obtained through such prediction algorithms tend to lack interpretability 
(Tuglus et al, 2008).  
1.1.2.3. Causal Inference Framework 
To facilitate the discussion, we let the observed data be represented by O= (A, W, 
Y) where A represents a set of binary biomarker variables, W a vector of covariates, 
and Y the clinical outcome of interest.  Thus, we define the observed data as   
     ,  the counterfactual outcomes of interest as   , and the full data as  
     
   , a   A), where a   {0,1}.  Under the general assumption of no unmeasured 
confounders, known as ignorability of the treatment assignment mechanism (Rubin, 
1978), the causal inference framework seeks to answer the following question: what 
is the causal effect of a given biomarker A on the clinical outcome Y? 
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   One possible measure of impact of a biomarker on the outcome, in the causal 
inference framework, is the marginal effect at the population level, known also as the 
average treatment effect.  It is estimated as:  E(  ) –E(  ), where    is the outcome 
the subject would have had if s/he received treatment, and    is the outcome the 
subject would have had if s/he received control.  However, in the observed data, 
instead of (  ,   ), only one outcome is possible for each subject such that Y=  A +    
(1-A),where   =1 and   =    if subject i was exposed to treatment; and   =0 and 
  =    if the subject was  not exposed (control).  The use of counterfactuals allows 
one to cast the problem as a missing data issue and thus opens the way to finding an 
approximation for the potential outcome.  Popularized by Rubin (1978, 2004, 2005), 
the counterfactual paradigm relies on one key assumption: Each subject in the 
sample has potential outcomes in two states, the one in which the subject is observed 
and the one in which the subject is not observed. Thus, each subject has in theory 
two counterfactuals     and    (Winship and Morgan, 1999).  This potential outcomes 
framework allows one to estimate the unobservable difference for each subject 
between outcomes under both conditions.  For more detailed technical discussions 
and applications of counterfactuals, see Robins et al (2000), Greenland and 
Brumback (2002), Petersen et al. (2006), Gelman and Meng (2004), Holland (1986), 
Rosenbaum (2002), Rubin (2005), D'Agostino (1998), Sobel (1995), Morgan and 
Winship (2007), West, Biesanz, and Pitts (2000), Winship and Morgan (1999); and 
Winship and Sobel (2004). 
In randomized studies, treatment assignment is independent of a subject’s 
potential outcomes.         Therefore, the difference of the sample averages E {  |A=1}- 
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E {  |A=0} equals E {Y|A=1}- E {Y|A=0} and  is an unbiased estimate of the 
population average casual effect , E(  ) – E(  ). In observational studies, exposure is 
not controlled, thus treatment received may not be independent of potential 
outcomes.  In this case, E {  |A=1}- E {  |A=0} may not be an unbiased estimate of 
the average treatment causal effect.  One way to account for this dependency is to 
find all important covariates (W) related to both potential outcome and treatment 
exposure and use them in the estimation of the population average causal effect.  The 
covariates W are chosen such that the potential outcomes     and    are independent 
of A|W. In other words, if W contains all confounders, then among subjects sharing 
the same W, the potential outcomes (  ,   ) and A are independent conditional on W 
( As would be the case in a blocked experiment where the treatment or biomarker A 
would be randomized within the levels of W).  In this case, E{E(Y|A=1, W)}= 
E{E(  |1, W)}= E{E(  |W)}=E(  ) and similarly, E{E(Y|A=0, W)}= E(  ), and E(  ) 
– E(  ) would be an unbiased estimator of the average causal effect.  For a deeper 
insight into how to choose W, refer to Cole and Hernán (2008), Schafer and Kang 
(2008), Robins (2001), Hernán et al (2002), Brookhart et al (2006). 
Robins has developed a class of models known as marginal structural models 
(MSM) whose aim is to ―replicate the findings of a randomized controlled trial using 
observational data‖. (Petersen et al., 2006).  These models allow one to estimate the 
average effect of a treatment or biomarker.  Below, we will list the assumptions 
behind MSMs and we will review three MSM estimators: G-computation, inverse 
probability of treatment weighting (IPTW), and double robust (DR) estimator 
(Robins et al., 1998, 2000; Hernán et al., 2001).  We will also provide an overview of 
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a new double robust method known as targeted maximum likelihood estimation. For 
simplicity, we assume a point-treatment study. 
The causal inference methods lie on the following assumptions: 
a. Consistency: The data for a subject is simply one of the counterfactual 
outcomes from the full data.  The observed data is        ). 
b.  Randomization: A    | w,   A. In other words, there are no unmeasured 
confounders for A, which means within strata of W, A is randomized. 
c.  Experimental Treatment Assignment Assumption (ETA):              
for all W.  
Of the three above assumptions, only the ETA is verifiable. For a more complete 
description of these assumptions and their practical applications, we refer to Cole 
and Hernán (2008) and Cole and Frangakis (2009).  Based on these assumptions, 
the likelihood of the data can be written as                   , where p could 
be a logistic function.  While some of the methods described below make 
assumptions only about       , others use         , and some  make assumptions 
about both conditional distributions (i.e. both        and         ). 
1.1.2.3.1. G-computation 
The G-computation (Robins, 1986, 2000) is a method used to estimate 
counterfactuals means.  It assumes that          is correctly estimated.  It relies on 
the following general formula: Pr (  =1) =                      .   
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For a dichotomous outcome Y, Pr (  =1) = E(  ) =                     , 
(E denotes Expectation).  The G-Computation estimate of the counterfactual mean in 
the simple context of point-treatment is then   [  ]=  
 
 
 
   [Y|A=a, W=  ].  This 
estimate can then be used to derive causal parameters such as risk difference, 
relative risk, and odds ratio.  To estimate the causal risk difference, for instance, one 
has to first postulate a model for the outcome regression E (Y|A,W), fit the model, 
and then average the resulting estimates E(Y|A=1, W)- E(Y|A=0, W) over all 
observed W.  Assuming a logistic function, Log 
         
         
       , the risk 
difference is    = E (Y|A=1, W) - E (Y|A=0,W)= 
        
          
 - 
      
        
 .  Then, the 
parameter of interest for the average causal effect   is estimated by plugging the 
maximum likelihood for the parameters    and   into the above equation and then 
averaging over all observed  : 
    =
 
 
      
   
       
      
       
- 
       
          
}. 
1.1.2.3.2. Inverse Probability Weighting 
The inverse probability treatment weighting (IPTW) approach relies on the 
correct specification of postulated propensity score model for a good performance.  
We will first present a brief review of the propensity score method followed by a 
summary of the IPTW methodology. 
1.1.2.3.2.1. Propensity Score 
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Assuming a logistic regression model, A|W~ bin (1, p
A|W
),       
          
          
     + 
    , the propensity score is defined as e(W) = P(A = 1|W)= 
         
            
. In short, it 
is the conditional probability of assignment to exposure A given a vector of observed 
covariates (Rosenbaum and Rubin, 1983; Mansson et al., 2007). As can be seen from 
this equation, it is dependent on the random variables W and has its own probability 
distribution. 
Because observed differences in observational data may reflect underlying 
differences between groups, it is critical to mitigate bias resulting from the 
imbalance in covariate distributions. The use of propensity score does improve 
comparability of exposure groups with regards to measured covariates, and thus 
decreases bias.  Given e(W), W and A are conditionally independent, which balances 
measured covariates across exposure groups (Rosenbaum and Rubin, 1983;Mansson 
et al., 2007). In other words, groups with similar distributions of e(W)  should have 
similar distributions of W .  Other properties of the propensity scores are as follows: 
a) If it is sufficient to adjust for covariates W, then it is sufficient to adjust for 
their propensity scores e(W) (Joffe and Rosenbaum, 1999);  
b) Estimated propensity scores do a better job at removing bias than true 
propensity scores , because the estimated propensity scores remove both 
systematic and chance imbalances, while the true propensity score removes 
only systematic imbalances (Joffe and Rosenbaum, 1999; Cepeda et al., 
2003). 
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Propensity scores have gained in popularity and have been widely used in 
statistical literature to control for baseline differences.   These adjustment methods 
range from matching (Rosenbaum and Rubin, 1985; Rubin and Thomas, 1996) to 
regression adjustment (D’Agostino, 1998; Rubin and Thomas, 2000) to weighting 
(Robins,1997;Robins et al., 2000; Hirano and Imbens, 2001; Sato and Matsuyama, 
2003).    
The selection of the propensity score model is often achieved through logistic 
regression.  The logistic model      
          
          
     +       does assume a linear 
relationship between the response and the covariates.  This assumption, however, is 
not always tenable, especially when some of the covariates are continuous. 
Moreover, Kang and Schaffer (2007) have shown that logistic regression might not 
always be a good way to estimate response propensities, and have advocated for the 
use of more robust procedures, especially in the presence of outliers.  One alternative 
approach to logistic regression has been a modeling framework that estimates a 
flexible function of the covariates while relaxing the linearity assumption.  One such 
model is the generalized additive model (GAM) for binary dependent variable.  
Pioneered by Hastie and Tibshirani (1990), the GAM assumes that the mean of the 
dependent variable depends on an additive predictor through a nonlinear link 
function, and allows the response probability distribution to be any member of the 
exponential family of distributions, including logistic model for binary data.  It 
allows for a more flexible relationship between continuous covariates and response 
by using smoothing techniques (Hastie and Tibshirani, 1990). 
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While the logistic regression models the logit of the response probability with the 
linear form      
        
        
     +      
 
   , the logistic additive model replaces this 
linear predictor with an additive one of the form:      
        
        
     +    
 
       , 
where    (.),   (.),…,  (.), are smooth functions that define the additive component.  
In this setting, the predicted probabilities, or propensity scores, are given by 
           
 
       
 
   
     
    
       
 
   
     
  and 
                       
 
    
       
 
   
     
 .     
The benefits of using GAM over logistic regression in estimating propensity 
scores have been demonstrated by Woo and colleagues (2008).  Using both 
simulated and genuine data, they showed how GAMs outperformed logistic 
regression in improving covariance balance, particularly for higher moments of the 
covariate distributions.  
In the case of continuous A, a flexible parametric approach, proposed by Irano 
and Imbens (2004) can be used to compute a generalized propensity score.  First, 
one postulates a normal  distribution of the continuous biomarker A given the 
covariates, i.e.              
 
 
     
  .  Then the parameters   ,   ,  
  are 
estimated by the least squares regression or by maximum likelihood estimation 
(MLE).  The generalized propensity scores are estimated by plugging in these 
parameter estimates into the normal density:      
 
     
       
             
   
   . 
1.1.2.3.2.2. IPTW Methodology 
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From the likelihood of the data                    ,  the inverse weighting 
method uses the treatment assignment distribution       to create a pseudo-
population in which the treatment assignment is no longer confounded ( Robins, 
1998).  Rather than using the difference of simple averages E(  ) – E(  ), this 
method estimates   , the average causal effect, by the difference of inverse 
propensity score weighted averages, i.e.         =
 
 
 
     
        
 
     
 
 
 
        
          
 
    , 
where e(W,   ) is the postulated propensity score model for the true propensity 
score.   
The first step in the implementation of the IPTW approach is to fit a multivariate 
regression of the probability of the biomarker A given the covariates W.  This model, 
referred to as the treatment mechanism (Petersen et al., 2006), is used to compute 
propensity scores. Then, each subject in the sample is assigned a weight SW equal to 
the inverse probability of being in a certain group    given their observed covariates 
W.  The higher the probability of a subject being in   , the lower the weight assigned 
to this subject; and vice versa. The end result is a pseudo dataset where the 
treatment is randomized.  Finally, a regression model of the outcome Y on the 
biomarker     with observations weighted by SW is fitted to estimate the IPTW 
parameter.  For an in-depth look at the IPTW methodology, see Robins (1986, 1998), 
Robins et al. (2000), Greenland and Brownback (2002).  
This method of weight estimation may suffer from a shortcoming whenever W is 
strongly associated with A, especially in non-saturated models.  In such occurrences, 
the weights might have large variability.  Studies by Kang and Schaffer (2007) have 
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shown how unstable propensity score weights could result in a poor performance of 
the IPTW estimator.   A solution proposed by Robins has been to use stabilized 
weights instead.  Instead of using 1 as the numerator in the weight computation, it is 
recommended to use the sample proportion of subjects having      (where a={0,1} 
is the set of all potential values of a given biomarker   ).  Denote the stabilized 
weights by   
       , where   
         
       
          
 . In practice, stabilized weights 
can be computed following the same basic steps taken by Cole and Hernán (2004).  
These steps are: 
1. Estimate the propensity score model with covariates and obtain the predicted 
values. 
2. Estimate the propensity score model without covariates by fitting an 
intercept-only model and generate the predicted values. 
3. Obtain the ratio of the estimates obtained in (a) and (b).  This gives the 
stabilized weights for each subject: estimates in (b) over estimates in a. 
For continuous A, the estimated stabilized weights are computed as a ratio of 
densities (i.e,       
   
     
) as proposed in Robins et al (2000).      is the marginal 
density of the continuous biomarker A, and        is the conditional density of the 
biomarker A given the set of covariates W. One way to estimate the numerator     is 
to specify a normal distribution (i.e.           
   , and then plug  the mean     and 
the empirical variance      of the biomarker A values  into the normal density. The 
denominator is estimated based on the generalized propensity score method of 
Hirano and Imbens (2004) described in the propensity score sub-section above.  
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1.1.2.3.3. Doubly Robust (DR) Estimator 
The DR estimation method combines both the G-computation and the IPTW 
approaches, by incorporating both          and       .  Under this method, the 
average causal effect is estimated as:  
     =
 
 
  
     
      
 
    
           
      
         ] -  
 
 
  
        
        
 
    
           
        
         ]      
 
=                                                                                                       
In the above equation, e(W,ß) is the postulated model for the true propensity score 
(from logistic regression);   (W,   ) and   (W,   ) are the postulated regression 
models for the true relationship between the vector of covariates and the outcome 
within each level of treatment A ( i.e. E(Y|A=0, W) and E(Y|A=1, W) ).  
While the G-Computation relies on the consistent estimation of P(Y|A,W) and  
the IPTW assumes that P( A|W) is correctly specified, the DR method produces 
consistent estimates as long as either one of the two models (propensity score or 
outcome regression model) is correctly specified (Robins and Rotnizky, 2005).  
Because of this property, referred to as double robustness, this approach presents a 
notable advantage, especially in situations where it might be easier to correctly 
specify the relationship of the biomarker with covariates or in situations where it 
might be easier to model the relationship between the clinical outcome and the 
biomarker and covariates.  Moreover, this approach presents a clear alternative 
whenever concerns linger about the correct specification of either the IPTW model 
(P( A|W)) or the G-computation model (P(Y|A,W)).  For an extensive review of the 
DR estimator, the reader is directed  to Robins and Rotnitzki (1995, 2001), Van der 
Laan and Robins (2003), Lunceford and Davidian (2004), Carpenter et al. (2006), 
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Davidian et al. (2005), and to Kang and Schafer (2007).  A SAS macro for doubly 
robust estimation and a companion book chapter by Funk et al. (2010) are available 
at http://www.unc.edu/~mfunk/dr/. 
1.1.2.3.4. Targeted Maximum Likelihood Estimation 
In a seminal paper published in 2006, Mark Van der Laan pioneered a new way 
to establish a ranking of biomarkers.  Considered as free from standard model 
assumptions, this method known as targeted maximum likelihood is employed, 
among other purpose, to generate a marginal variable importance measure that 
captures the impact of each biomarker on an outcome (Van der Laan and Rubin, 
2006). For a formal and theoretical discussion, refer to Van der Laan and Rubin 
(2006), Van der Laan, (2005); for empirical examples or applications in biomarker 
selection, see Bembom et al. (2006, 2008), Tuglus and Van der Laan (2008).  It has 
been shown through simulations studies that this method has good statistical 
properties (adequate bias-variance tradeoff, efficiency, consistency, robustness) and 
that that the variable importance measure obtained under the TMLE can be, under 
certain conditions, a doubly efficient and robust measure that accommodates both 
low and high dimensional data (Van der Laan and Rubin, 2006; Bembom et al, 
2008; Tuglus and Van der Laan, 2008).  
The TMLE methodology achieves double robustness by applying both the G-
computation and the IPTW models simultaneously.  The parameter of interest, 
which measures the true marginal importance of each biomarker A with regards to 
the outcome Y, is  =   [E(Y=1|   =1, W) - E(Y=1|   =0, W)] (for each biomarker, 
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indexed by j).  In practice, implementation of the targeted maximum likelihood 
estimation (TMLE) to generate a targeted measure of variable importance (TVIM) 
involves adding a covariate h(A,W) (stretching function) to an initial regression 
model denoted by   (A,W), and then averaging the regression over the covariates for 
fixed value of A (Van der Laan and Rubin, 2006).  In the repeated measures setting, 
targeted maximum likelihood estimation of the variable importance measure takes 
time into account.   More specifically, for a time-varying outcome Y(t), the parameter 
of interest is given by:  (t) ≡ Ew [ E (Y(t)/Aj =1, Wj) - E (Y(t)/A j=0, Wj) for discrete 
A.  Incorporating time in the objective function allows one to estimate the impact of 
each biomarker on the time trajectory (Bembon et al., 2006). 
Simulation studies and application of the TMLE to real data have generated 
promising results.   Analyses performed by Tuglus et al. (2008) have shown TMLE 
has generated a list of differentially expressed genes in patients with acute 
lymphoblastic leukemia and acute myeloid leukemia, that shows greater biological 
plausibility than results obtained from univariate least squares regression, penalized 
least squares regression (Least Absolute Shrinkage and Selection Operator (LASSO) 
regression), and random forest.  Likewise, Bembon et al. (2008) applied the TMLE 
methodology to data from the Stanford Drug Resistance Database to generate 
measures of impact for a set of candidate genetic mutations with regards to their 
importance in conferring resistance to the protease inhibitor drug Lopinavir.  In this 
analysis, the ranking of genetic mutations based on the TMLE methodology was in 
best agreement with current medical knowledge, as compared to results from 
univariate least squares regression and G-computation. 
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1.1.2.3.5. Classifier Performance Assessed by ROC Curve 
As a tool for assessing diagnostic accuracy, the Receiver-Operating Characteristic 
(ROC) curve has received a great deal of attention in the statistics literature (Begg, 
1991; Hanley, 1989; Faraggi and Reier, 2002).  Originally used in the signal detection 
theory developed in the 1950s (Green et al., 1996), this technique has been, over the 
years, extended to a variety of research fields including radiology (Obuchowski, 
2005; Hanley, 1998; laboratory testing (Obuchowski et al.,2004; Zweig and 
Campbell, 1993), epidemiology (Pepe, 2000, 2003; Pepe and Janes, 2008; Baker, 
2003; Pencina and D’Agostino, 2004), bioinformatics and machine learning (Li and 
Fine,2008; Provost and Faucett, 2001; Lasko et al., 2005, Kjetil, 2009), and 
countless other clinical disciplines (Zheng et al., 2006;  Zou et al.,2007; Musial et al., 
2003, Cheun et al.,2001). 
Let X be a binary test result and D the outcome (disease or not).  Condition on 
disease status, two basic measures of performance for a binary test are sensitivity 
and specificity (Pepe, 1983).  Sensitivity is defined the fraction of subjects with 
disease that a diagnostic test correctly identifies as positive (true positive fraction 
(TPF), i.e. P[Y = 1|D = 1]) while specificity is the fraction of subjects without the 
disease that the test correctly identifies as negative (true negative faction, i.e. P[Y = 
0|D = 0]). The quantity 1 – specificity is called false positive fraction (FPF) and 
represents the probability of a positive test given that disease is not present (i.e. P[Y 
= 1|D = 0]). 
The ROC curve generalizes the notions of FPF and TPF to continuous tests X.  
Assuming that a test is classified as positive if Y is above a threshold c , then TPF(c) = 
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P[Y  c| D = 1] and FPF(c) = P[Y  c| D = 0], and ROC(.) = {(FPF(c), TPF(c)), c 
ϵ       } (Pepe, 2000).  The ROC curve is a plot of the test sensitivity (TPF) along 
the y axis versus its 1-specificity (FPF) along the x axis, for all possible threshold 
values c (Heagerty at al., 2000). In mathematical terms, it can be written as      = 
      
         t   (0,1) where   and    are survivor functions for the test result  in 
the diseased (cases) and non-diseased (controls) populations.  It is a monotone 
increasing function in (0,1) that can be estimated both parametrically and non-
parametrically (Hanley et al., 1982a & 1982b; Zou et al., 1996; Hanley, 1988; Metz, 
1978).  More complete assessments of the performance, advantages or disadvantages 
of either parametric or non parametric estimation methods of the ROC curve are 
available in Hajian-Tilaki  et al. (1997), Goddard (1989), and in Faraggi and Reiser 
(2000). 
1.1.2.3.5.1. Area Under the ROC Curve and Partial Area Under the 
ROC Curve  
The most commonly used summary ROC Index is the area under the ROC curve 
(AUC).  In general, AUC=         
 
 
, AUC   [0,1]. It is interpreted as the 
probability that the test result from a randomly chosen diseased individual is more 
indicative of disease than that from a randomly chosen non diseased individual 
(Pepe, 2000).  As a rule of thumb, a more convex ROC translates in a better 
classifier, and so does a higher AUC.  At AUC=1, the discrimination /accuracy of the 
classifier is deemed perfect.  An AUC=0.5 reflects pure noise conditions, thus an 
uninformative test (Kjetil, 2009; Pepe , 2003).  Both parametric estimation through 
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the binormal model (Swets and Pickett, 1982) and nonparametric estimation 
through the Wilcoxon Mann-Whitney U-statistic (Bamber, 1975; Hanley and McNeil, 
1982a & 1982b) are available for the AUC statistic. 
One notable pitfall often attributed to the AUC measure is its lack of clinical 
relevancy (Dodd and Pepe, 2003). As Obuchowski (2005) points out, the ROC curve 
extends well beyond the clinically relevant area of potential clinical interpretation.  
More often than not, the interest lies in only a fraction of the ROC space that 
corresponds to clinically relevant values of test specificity and sensitivity.  For 
instance, in using CD4 cell count level as a determining factor for starting HAART 
therapy, a low false positive rate may be desirable, thereby making the lower tail of 
the ROC curve the region of interest.  This is one of the cases where it may not make 
sense clinically to look at the whole ROC curve.  In response to situations like this, a 
measure with greater clinical appeal, that considers only regions of interest in the 
ROC space, has been developed.  It is called partial AUC (McClish, 1989; Thompson 
and Zucchini, 1989) and it focuses on a limited range of false positive rates. The 
partial AUC does also provide notable benefits when two ROC curves cross.  Analyses 
by Zhang et al. (2002) and by Fawcett (2006) show that partial ROC analysis tends 
to provide more information and helps better with clinical decision making in cases 
of two crossed ROC curves.  For false positive rates (FPR) Є (0, t) for some t < 1, the 
partial area under the curve is defined as pAUC=         
 
 
 and can be estimated 
both parametrically and non-parametrically. For partial AUC estimation methods, 
inference, and statistical properties of the estimator, see   McClish (1989), Wieand et 
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al. (1989), Zhang et al. (2002), Pepe (2003), Dodd and Pepe (2003), Janes et al. 
(2005), Cai and Dodd (2008).   
1.1.2.3.5.2. Incorporation of Covariates Information in ROC 
Curves  
While the ROC curve and the AUC have been extensively studied in statistical 
literature and are widely used to assess classifier performance, there has been until 
relatively recently a gap in the search for standards methods of incorporating 
covariate information in ROC curves.  This topic has now received increased 
attention, and for practical reasons: Covariate adjustment can help eliminate 
potential confounding (Huang and Pepe, 2009).  Janes and colleagues (2006, 2007, 
2008) argue that without covariate adjustment, ROC curves can be differentially 
biased, which can lead to faulty marker comparisons.   
A discussion of different uses of covariates in ROC analysis can be found in Janes 
and Pepe (2007, 2008a, 2008b, 2008c) and in Janes, Longton, and Pepe (2008).  
These authors have made a clear distinction between covariate adjustment and other 
related uses of covariates. Adjustment is recommended when the covariate W affects 
the distribution of the marker among controls.   A relevant measure of classification 
accuracy in this case would be the covariate-adjusted ROC Curve (AROC), a stratified 
measure of ROC performance (Janes and Pepe, 2006; Janes and pepe, 2007; Janes, 
Longton, and Pepe, 2008).  Procedures for deriving the AROC and other related 
metrics of biomarker comparison such as the area under the adjusted ROC curve 
(AAUC) are provided in Janes, Longton, and Pepe (2008). 
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In situations where the covariates W affect the separation between case and control 
distributions (i.e. affect discrimination), Janes and colleagues recommend ROC 
regression as a way to dealing with covariates.  Two examples of covariates that fall 
in this category are disease severity and specimen storage time. In the ROC 
regression setting, the end result is an estimate of the ROC curve as a function of 
covariates (covariate-specific ROC curve).    
The third approach to incorporating covariate information in ROC analysis is the 
incremental value estimation.  This approach takes hold when the covariates W are a 
set of risk factors or other baseline predictors (Janes, Longton, and Pepe, 2008).  For 
these factors that contribute to discrimination, Janes et al. (2008) recommend 
combining the biomarker and covariate information and determining the 
incremental value of the biomarker beyond and above the covariates.  Typically, two 
models containing both the covariates, but with and without the biomarker are 
fitted.  ROC curves comparison is then made for the linear predictions from the two 
models.  A similar approach has been implemented in the analysis of the 
Atherosclerosis Risk in Communities Study to determine, among a panel of 19 novel 
biomarkers, those with the biggest increase in AUC for CHD prediction above and 
beyond a set of covariates (Folsom and Chambless, 2006). Additional examples of 
implementation of this method to assess discrimination of biomarkers above and 
beyond that of classic cardiovascular disease risk factors can be found in Danesh et al 
(2004), Koenig et al (2004), Pepe et al (2004), Ricker et al (2002), Rutter et al 
(2004), Shlipak et al (2005), Van der Meer et al (2003), and Wilson et al (2005). 
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1.1.3. Remaining Statistical Challenges 
The methods summarized above do have their merits, but they are not are not 
exempt from shortcomings.  Despite all the advances in the statistical analysis of 
biomarker data, some critical challenges remain.   
a. The t-test does not control for confounding and tends to lack robustness, 
especially in high throughput data (Tuglus et al., 2008; Yu et al., 2006).  
While classical multivariable regression methods provide an analytical 
framework where all biomarkers can be evaluated simultaneously with or 
without covariate adjustment, they tend to be unstable when multicollinearity 
exists.  Furthermore, they are prone to model misspecification, may not even 
be feasible when the data are high dimensional, and ultimately, may lead to 
biased estimates of the variable importance measures (Tuglus, 2008).  As for 
the most commonly used summary Index of the ROC curve, the Area Under 
the ROC curve (AUC), it can lack clinical relevancy (Dodd and Pepe, 2003; 
Obuchowski, 2005).  Finally, non-linear models and machine learning 
techniques, while considered as valuable tools for biomarker selection and 
classification in high throughput datasets, tend to be complex to non 
sophisticated users and are generally computationally intensive (Levy et al., 
2005). 
b. There is no unifying framework for biomarker selection.  Different ranking 
features applied to the same data often generate different rankings of 
biomarkers.  For instance, Dutkowski and Gambi (2007) used a proteomic 
mass spectrometry dataset to evaluate several feature selection methods and 
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ended up with different feature lists.  This confirms earlier findings by Levy et 
al. (2005).  In all methods, the goal and expectation should be to generate a 
reliable list of the top-ranked candidates that are significantly associated with 
the outcome of interest.  Having different lists can be counterproductive and 
constitutes an impediment to the efficient use of biomarkers.  Thus, the 
question of creating, through methods with good statistical properties, unified 
biomarker lists for further biologic examination or for subsequent statistical 
assessment of surrogacy, remains an open one.   To increase the use and 
utility of biomarkers in drug development and public health research, these 
statistical issues need to be addressed. 
c. Methods based on the causal inference framework, and more specifically the 
targeted maximum likelihood estimation for variable importance measure, 
are promising approaches that are worth exploring.  However, the TMLE, as a 
novel method, has not been widely applied in public health and 
pharmaceutical research. To our knowledge, there has been no systematic 
comparison between this method and other statistical approaches in their 
ability to select and rank biomarkers in different settings: cross-sectional, 
longitudinal, and time to events.  Furthermore, there have been no 
established guidelines for data collection and assessment based on this 
method.  
This dissertation aims at filling these research gaps by addressing the core issue 
of biomarker selection in the presence of covariates. It is worth noting that most of 
the methods mentioned above are used for biomarker screening where the goal may 
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be to find all biomarkers that are statistically significant.  This research does go one 
step further by applying methodologies aimed at identifying, from a set of candidate 
biomarkers, the ones that are the most important in terms of their contributions to a 
clinical outcome.  In short, the aims here are beyond biomarker screening and 
encompass variable importance assessment and ranking. 
1.1.4. Multiplicity Considerations in Biomarker Research 
In biomarker studies, large number of hypothesis tests are often conducted to 
identify candidates associated with an outcome.  This gives rise to a multiple 
hypothesis testing problem.  Suppose that m independent tests are conducted, the 
probability of at least one false positive result is 1 -        and converges to 1 as m 
increases.  For instance, this probability jumps from 0.226 to 0.994 if the number of 
tests m increases from 5 to 100.  In microarray gene expression experiments, for 
instance, thousands of genes are often examined.  With this high number of 
simultaneous hypotheses tests (one for each gene), the probability of obtaining at 
least one false positive result is near certainty.  In such cases, one needs to adjust for 
multiple testing.  
The goal of multiple testing is to minimize the type I error while maximizing power.  
Traditional multiple comparison procedures such as the Bonferroni correction 
impose a penalty for multiple testing.  This penalty can, however, be too stringent 
(Devlin et al., 2003).  As the number of test increases, traditional adjustment 
methods such as the Bonferroni procedure become powerless.  A competing 
approach to multiple testing, that is more powerful, more liberal, and that is now 
widely used, is based instead on controlling the false discovery rate (FDR).  With this 
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new approach that allows a reasonable number of false discoveries, the goal shifts 
from controlling the family-wise error rate to keeping in check the expected 
proportion of false discoveries (Benjamini and Hochberg, 1995, 2000).  
  Suppose that m is the total number of null hypothesis tested (   , 
   ,…,    . Furthermore, let   ,   ,…,    be the p-values obtained from those tests. 
Denote by F the number of false positives (i.e. type I error), by T the number of true 
positives, and by S the total number of rejections (i.e. F + T) and define Q= 
 
 
 
        
           
 .  The false discovery rate (FDR) is E( Q), or expectation of proportion 
of type I errors among all rejections.  The Benjamini and Hochberg method controls 
the FDR at level  
  
 
q  q and works as follows: 
a. Order the m p-values     ,     ,…,     from smallest to largest, and order the 
corresponding hypotheses:      ,     ,…,     . 
b. Set a threshold value for rejection by finding the largest integer i such that 
       , i.e.  k= max{ i:      
 
 
 }.  If no such integer i exists, then no 
hypothesis is rejected. 
c. Reject any hypothesis with a p-value      
The Benjamini and Hochberg FDR-controlling step-up procedure works on the 
assumption of independence. It further assumes that the true null hypotheses p-
values are uniform (0,1) random variables under the null hypotheses.  It has been, 
however, demonstrated in literature that the Benjamini and Hochberg procedure 
does control the FDR under some dependency structures (namely positive 
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dependency) and covers  many problems of general interest (Benjamini and 
Yuketieli, 2001).  For a greater range of dependency problems, a simple modification 
of the Benjamini and Hochberg procedure has been proposed by Benjamini and 
Yekutieli (2001) to control the FDR. Known as the Benjamini and Yekutieli FDR 
controlling procedure, this method sets the threshold for rejection at: k= max{ i: 
     
 
 
  }, where      
 
 
 
 
 
   
.  It always controls the FDR at level less than or equal 
to 
  
 
q (Benjamini and Yekutieli, 2001). 
For in-depth discussions and comparisons of multiple comparison procedures, 
including FDR, see Benjamini and Hochberg (1995, 2000), Yekutieli and Benjamini 
(1999), Benjamini and Yekutieli (2001), Genovese and Wasserman (2002, 2003),  
Storey ( 2002, 2003), Storey and Tibshirani (2001, 2003), Finner and Roters 
(2002), Dmitrienko et al. (2005), Dudoit, Shaffer, and Boldrick (2003), Westfall 
et al. (1999), Brown and Russell (1997), and Pollard, Dudoit, and Van der Laan 
(2004).  
1.1.5. Specific Aims of the Research 
The past decade has seen an explosion in the availability and use of biomarkers 
data as a result of innovative discoveries in areas such as combinatorial chemistry, 
mass spectrometry, high throughput screening, DNA microarrays, and proteomics.  
This has been accompanied by a growing emergence of biomarkers as a topic of 
clinical research. Publications identified by the keyword ―biomarker‖ in Pub Med  
from 1999 through 2008 have increased dramatically and reached a peak of 37,000 
in 2007 (Wagner, 2009).  With that explosion of data come new challenges.  A good 
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fraction of biomarkers data are high-dimensional and do not lend themselves to 
standard statistical methods.  Also, due to the large number of candidate biomarkers 
for a given condition, selection of the ones with maximal impact has become a 
critical issue.   An effective biomarker discovery streamlining process could help save 
time and previous resources by directing researchers’ focus on the best candidates.  
On the other hand, choosing the wrong candidates could lead to incorrect decision-
making about potentially effective agents.  Major advances in biomarker discovery 
underscore the need for novel statistical methods, especially in the area of biomarker 
selection.  Even though several statistical methods have been proposed as solutions 
to the biomarker selection problem, there are still some major hurdles. So far, there 
is no unified approach for biomarker selection.  Different methods tend to generate 
different results.   Some of the newest methods, although promising, have had 
limited use in clinical research and lack clearly-established guidelines for sample size 
calculation and power analysis in studies involving biomarker selection.  To increase 
the use and utility of biomarkers in drug development and public health research, it 
is imperative that these statistical issues be addressed. 
The proposed dissertation project seeks to fill this gap by addressing the core 
issue of biomarker selection in the presence of covariates. Its primary aim is to 
examine the effectiveness of three novel statistical methods in identifying 
biomarkers with good performance characteristics. It also seeks to provide 
guidelines for data collection and assessment, such as sample size computation and 
power analysis, in studies involving biomarker selection where these methods are 
37 
 
employed.  It uses real and simulated data to apply these innovative statistical 
methods to the concrete issue of biomarker selection in the context of HIV infection.   
The specific objectives of this research are: 
1. To estimate a marginal variable importance measure (VIM) separately for 
each biomarker that determines the clinical outcome CD4 cell count using 
the following estimation methods: Targeted Maximum Likelihood, Binary 
Regression based on flexible propensity score estimation, Incremental Value 
Estimation based on partial Receiver Operating Characteristic (ROC) Curve 
methodology, and weighted Cox proportional hazards model.  
2. To use variable importance measures computed in (1) to make inference 
about the importance of each biomarker.  This would help determine 
whether there exist, among all the biomarkers considered, more affordable 
alternatives that can accurately predict CD4 cell count. 
3. To develop an index that represents a longitudinal measure of the 
importance of each biomarker over time. 
4. To establish guidelines for future data collection and assessment, based on 
results from simulations. 
These specific aims have been addressed in three separate papers.  The content 
of each paper is presented in the next three (3) chapters. 
 
  
 
 
 
 
CHAPTER 2 
 
 Comparison of the effectiveness of three novel statistical methods for 
biomarker selection with application to an HIV infection dataset. 
2.1. Introduction 
The importance of biomarkers both in the drug development process and in 
public health practice is well established.  Fueled by recent advances in modern 
biology and technology, biomarkers have become a popular research topic in clinical 
investigations.   Publications identified by the keyword ―biomarker‖ in PubMed  from 
1999 through 2008 have increased dramatically and reached a peak of 37,000 in 
2007 (Wagner, 2009).  With that explosion of data come new challenges.  An 
overarching aim is to find ways to use this wealth of biomarker information to help 
guide clinical decision making.  Therefore, the development of improved statistical 
methods that can adequately explain the relationship between biomarkers and an 
outcome, is of great interest.  One domain that is evolving in this regard concerns the 
quest for variable importance measures, a class of estimators that could reliably 
capture the effect of a specific biomarker on a clinical outcome.  Such estimators are 
used in the identification, among many candidate biomarkers, of the best subset that 
is significantly associated with an outcome of interest.  This could help reduce waste 
and time by directing biologists’ focus to top performing biomarkers, or by allowing 
practitioners to direct resources towards the most promising candidate biomarkers.   
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This paper addresses the core issue of biomarker selection in the presence of 
covariates, especially when the goal is to identify biomarkers with good performance 
characteristics from among a large number of candidates.  This research is the first 
of its kind to compare the performance of three novel statistical methods of 
biomarker selection and then use these estimators to address a major public health 
issue: the relationship of CD4 cell counts with other biomarkers in HIV-infected 
patients.  The contribution of this paper is enhanced by the fact that it evaluates the 
impact of finite sample size on the performance of these estimators.  
The outline of the paper is as follows. Section 2.2 provides an appraisal of current 
statistical methods for biomarker selection.  Section 2.3 discusses three novel 
methods for biomarker selection, while section 2.4 applies these methods to an HIV 
infection dataset.   Section 2.5 presents a Monte Carlo simulation to examine the 
behavior of the three methods under different sample sizes. Section 2.6 concludes 
and provides suggestions for further research. 
2.2. Current Statistical Methods for Biomarker Selection  
A survey of statistical methods used for biomarker selection reveals that both 
standard and novel statistical methods have been employed to address the 
challenges of biomarker selection.  The panoply of methods used in this regard 
includes the t-test (Dudoit el al., 2002);  classical multivariable regression 
techniques such as ordinary least squares and logistic regression; the Receiver-
Operating Characteristic (ROC) curve (Pepe, 2000, 2003); and non-linear models 
and machine learning techniques  such as classification and regression trees 
(Breiman et al., 1984), bagging (Breiman, 1996), boosting (Freund and Schapire, 
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1997), random forest (Breiman, 2001), and pattern recognition techniques (Vapnik, 
1998; Burges ,1998).  
All these methods suffer from shortcomings.  The t-test does not control for 
confounding and tends to lack robustness, especially in high throughput data 
(Tuglus et al., 2008; Yu et al., 2006).  While they provide an analytical framework 
where multiple biomarkers can be evaluated simultaneously, classical multivariable 
regression methods tend to be unstable when multicollinearity exists, are prone to 
model misspecification,  and may not even be feasible when the data are high 
dimensional.  The most commonly used summary index of the ROC curve, the Area 
Under the ROC curve (AUC) lacks clinical relevancy (Dodd and Pepe, 2003; 
Obuchowski, 2005).  Finally, non-linear models and machine learning techniques, 
while considered as valuable tools for biomarker selection and classification in high 
dimensional data, tend to be complex to non-sophisticated users and are generally 
computationally intensive (Levy et al., 2005).  Furthermore, there seems to be no 
unifying framework for biomarker selection.  Different ranking features applied to 
the same data often generate contrasting rankings of biomarkers.  For instance, 
Dutkowski and Gambi (2007) used a proteomic mass spectrometry dataset to 
evaluate several feature selection methods and ended up with different feature lists.  
This confirms earlier findings by Levy et al. (2005).  In all methods, the goal and 
expectation should be to generate a reliable list of the top-ranked candidates that are 
associated with the outcome of interest.  Having different lists can be 
counterproductive and constitutes an impediment to the efficient use of biomarkers.  
Thus, the question of creating, through methods with good statistical properties, 
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unified biomarker lists for further biologic examination or for subsequent statistical 
assessment of surrogacy, remains an open one.   To increase the use and utility of 
biomarkers in drug development and public health research, these statistical issues 
need to be addressed. 
An additional framework under which biomarkers are often evaluated is the 
causal inference paradigm. Under the assumptions of consistency, randomization, 
and experimental treatment assignment (Cole and Hernán, 2008; Cole and 
Frangakis, 2009), causal models enable researchers to estimate, among other 
measures, an average effect of a biomarker, which under certain conditions could 
carry a causal interpretation. Three of the most commonly used estimation 
techniques under causal inference approaches are G-computation (Robins, 1986, 
2000), inverse probability of treatment weighting (IPTW) (Robins et al., 2000; Cole 
and Hernan, 2008) and the double robust estimator (Van der Laan and Robins, 
2003).  Two of the methods used in this paper originate from this framework. 
2.3. Materials and Methods 
2.3.1. Study sample 
The dataset used for application in this paper came from the Hormonal 
Contraception and HIV Genital Shedding and Disease Progression or GS Study.  The 
GS Study is a prospective multicenter study of 306 HIV infected women aged 18 to 
45 years old from Uganda and Zimbabwe.  This study started in 2001 as an add-on to 
the HC-HIV study (Morrison et al., 2007) and was completed in the field in 
December 2009.  Women who seroconverted during the course of the HC-HIV study 
were recruited for the GS study, based on procedures outlined in Morrison et al. 
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(2010). The study specific objectives are described in details elsewhere (Morrison et 
al., 2007, 2010), but one key research question is the effect of hormonal 
contraception on the biological parameters of the infectivity of women with primary 
and chronic HIV infection to their sex partners. 
The GS consisted of a baseline visit and follow-up visits at 2, 4, 8 and 12 weeks 
following HIV seroconversion, and then every 12 weeks for up to 9 years.  Women 
who developed severe HIV infection or who had successive CD4 cell counts at or 
below 200 cells per mm3 were offered highly active antiretroviral therapy (HAART) 
and were seen twice a month for the first month, then monthly thereafter.  In 
addition to baseline demographic characteristics, at each time point, information on 
various laboratory parameters, reproductive variables, contraceptive exposure, and 
recent sexual behavior was collected.  Gathered laboratory data included HIV plasma 
viral load, HIV sub-type, CD4, CD8 and total lymphocyte counts, serum chemistries, 
lipid profiles, specimens for the detection of chlamydial, gonococcal, syphilis, herpes 
simplex virus 2 (HSV-2), and human papillomavirus (HPV) infections.  The study 
also collected information on hormonal contraceptive use, HIV disease progression 
parameters, as well as virologic, immunologic, and clinical responses to HAART 
among hormonal and non-hormonal contraceptive method users. For a detailed 
description of the study population and procedures, the reader is directed to 
Morrison et al. (2010).                                                                                
2.3.2. Data structure  
 
To facilitate the discussion of the methods, we let the observed data be 
represented by O= (A, W, Y) where A represents a set of either binary or continuous 
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biomarker variables, W a vector of covariates, and Y the clinical outcome of interest 
(Y=1 for diseased and Y=0 for non-diseased).  Define the observed data as   
     ,  the counterfactual outcomes of interest as   , and the full data as  
     
   , a   A), where a=(0,1) (binary case) or a   ={            (continuous case). 
The set of covariates (W) used in this analysis consist mainly of behavioral, 
reproductive, and demographic factors reported in the literature to be predictive of 
incident HIV infection or clinically associated with HIV disease progression (Van 
Der Pol et al., 2008).  These covariates included age, country, commercial sex work 
status, number of coital acts in previous 3 months, condom use consistency, study 
subject’s partner’s sexual behavior and risk, frequency of  nights away from home by 
study subject’s partner, history of sexually transmitted infections (STI), presence of 
STI symptoms at enrollment, having more than one sex partner, and breastfeeding.  
The vector of biomarkers A contained measures such as plasma viral load, HIV sub-
type, HIV RNA load, hemoglobin level, CD4, CD8  and lymphocyte counts, CD4/CD8 
T cell ratio, CD4 percentage, and HSV-2 status. The latest biomarkers and covariates 
measurements available at 6 months from estimated date of HIV infection were used 
in this analysis. While HIV sub-type and HSV-2 status were binary variables, all 
other biomarkers used in this analysis were measured on a continuous scale. 
In this analysis, we defined baseline as the latest biomarker measurement or 
covariate value available 6 months after estimated infection date.  The estimated 
infection date refers to the mid-point between the last visit where a subject was HIV-
uninfected in the HC-HIV study and the first visit where this subject was confirmed 
infected. Based on the timing implied by this definition of baseline, a number of 
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subjects might not have baseline data because of the length of time elapsed between 
the date they were notified of their HIV infection and their first GS-enrollment visit 
(where specimens for plasma and cervical viral loads were collected).  For these 
subjects, the GS enrollment visit might have occurred more than 6 months after the 
estimated infection date.  Thus, subjects with missing baseline biomarker 
information because of the timing of their first GS visit did not contribute data to the 
analysis. 
The clinical outcome (Y) was a binary variable representing two successive 
drops of CD4 cell count at or below 350 cells/mm3 in the first two years following the 
viral set point (i.e. 121 days following the estimated infection date).  The choice of the 
threshold of 350 cells per mm3 for the clinical outcome of CD4 was based on current 
guidelines for the use of antiretroviral agents in adults and adolescents infected with 
HIV-1 in the absence of an AIDS-defining illness (Panel on Antiretroviral Guidelines 
for Adults and Adolescents, 2008). Also, evidence from the literature suggests that 
initiation of antiretroviral therapy before the CD4 cell count has fallen below 350 
cells per mm3 significantly improves survival, as compared to deferred therapy (Sax 
and Baden, 2009; Kitahata et al., 2009; When to Start Consortium, 2009). 
2.3.3. Measures of Effect 
 
We implemented three methods to derive a marginal variable importance 
measure for each biomarker used from the GS Study.  These methods were: targeted 
maximum likelihood estimation (TMLE), propensity score weighting (PSW), and 
incremental value estimation for partial area under the ROC curve. 
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Under the TMLE and the PSW methodologies, the measure of effect for each 
binary biomarker was the difference in probabilities between those with and without 
the biomarker exposure of interest (A=1 vs A=0), averaged over the entire 
population:   
 =   [E(Y=1|   =1, W) - E(Y=1|   =0, W)].  
In the continuous case, the parameter of interest was:  
 =   [E(Y=1|   =a, W) - E(Y=1|   = , W)], where   is the empirical mean of the 
biomarker     
Under the incremental value scheme, the measure of variable importance was 
the incremental value, i.e. the amount of discriminatory accuracy of the biomarker 
   over and above the covariates (W).  Essentially, we estimated the optimal 
difference in partial AUC between a model with only covariates and a model with 
both the biomarker    and covariates, based on the following non-parametric 
estimator proposed by Dodd and Pepe (2003):  
            =
 
  
             
 
 
 
          ), (where          are sample quantiles; m 
and n represent the sample sizes from non-diseased sample    and from diseased 
sample   ). 
To generate standard errors for the estimates of the VIM measures obtained 
under each method, bootstrapping (Efron and Tibshirani, 1994) was implemented.  
We applied the following algorithm for bootstrap selection and for assessing multiple 
comparison: 
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1. From the original sample S, we drew B independent bootstrap samples 
            , each of size n, assuming simple random sampling with 
replacement. 
2.  For each bootstrap sample, we then computed the sample quantity of interest 
    This resulted into B values of the statistic    .   
3. The bootstrap estimator of the parameter   was given as the mean of the 
bootstrap estimates    
   =
 
 
    
 
   , with variance   (      
 
 
         
         .  
The standard deviation of the distribution of the statistic     was then:          
= 
 
 
         
             
4. We subsequently assessed the strength of the evidence for a non-zero effect by 
conducting the following test of hypothesis:          versus               , for 
each j (j=1,…, k).   
5. We repeated these steps k times, that is once for each biomarker       
1,……k to generate k estimates of    and k p-values denoted as P1, P2,…, Pk. 
6. Finally, we adjusted the p-values for multiplicity testing to control the false 
discovery rate.  The Benjamini and Yekutieli (2001) False Discovery Rate 
(FDR) controlling procedure was used to account for the dependence of the 
test statistics. Significance for each biomarker was assessed by comparing 
related adjusted p-value to the 0.05 alpha level.  A lower the p-value denoted 
a better measure of importance. 
Below, we present an overview of the three procedures. 
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2.3.4. Targeted Maximum Likelihood for Variable Importance 
Measure 
Developed by Van der Laan (2006), the targeted maximum likelihood 
estimation methodology is employed, among other purposes, to generate a marginal 
variable importance measure that captures the impact of a given biomarker on an 
outcome. For a formal and theoretical discussion, refer to Van der Laan and Rubin 
(2006), Van der Laan (2005); for empirical examples or applications in biomarker 
selection, see Bembom et al. (2008), Tuglus and Van der Laan (2008).  Under 
certain conditions, the variable importance measure obtained under the TMLE can 
be a doubly efficient and robust measure (Van der Laan and Rubin, 2006).   
We followed a three-step approach to implement this methodology.  First, we 
modeled the conditional distribution of Y given A and W using the following logistic 
mean model:                                    
 
    , where    represents the 
target biomarker variable, and    the vector of covariates listed in section IV.  From 
this outcome model, we generated fitted values denoted as    (A,W).   
Next, we estimated the conditional distribution of the biomarker given the 
covariates.  The predictors were the same set of covariates used in the outcome 
model.  For binary biomarkers (A), the estimates of the probabilities  (  =1| W) and 
 (  =0| W), denoted by   
  (A, W), A=0 or 1, were computed and then used to 
calculate a covariate h(A,W) as follows:          
      
  
       
  
      
  
       
 ), (where I 
denotes an indicator function).  For continuous biomarker (A), we followed Tuglus et 
al. (2008) and defined the covariate h(A, W) as:                 
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The next stage in applying the TMLE entailed updating the initial estimate 
  (A,W) with the covariate h(A,W) by regressing the binary outcome Y on the 
covariate h(A,W) in an intercept-only model where the initial estimates    (A,W) 
were held fixed. Specifically, the updated estimate   (A,W) is given by 
  (A,W)=(A,W)=  (A,W) + (         .  The regression coefficient   is obtained 
through maximum likelihood estimation (MLE) using    (A,W) as offset. From this 
regression, we obtained the maximum likelihood estimate   for the covariate h(A,W) 
and used   to update the  initial estimate of   (A,W) such that    (A,W)=   (A,W) + 
(             Finally, we computed the targeted estimate of the marginal variable 
importance measure of interest, for each binary biomarker, by evaluating   (A,W) at 
both   =1 and   =0 for  each individual i, and then averaging over all i.  For 
continuous biomarkers,   (A,W) was evaluated at both   =a and   =  . These steps 
were repeated for each biomarker.   
2.3.5. Propensity Score Weighting for Variable Importance 
Measure 
As in the TMLE, this method uses a counterfactual structure and the same two 
nuisance parameters: P(Y|A,W) and P(A|W).  The difference, however, lies in the 
algorithm we executed to update the initial estimates of P(Y|A,W).  While Van der 
Laan et al. (2006) add a covariate created from P(A|W) to the initial regression 
model, we used weights constructed from estimated propensity scores P(A|W) to 
incorporate the relationship between A and W in the estimation of P(Y|A,W).   
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 The generation of variable importance measures through the Propensity Score 
Weighting method was performed in three steps, as described below.  In the first 
stage, we estimated the propensity scores.  For binary biomarkers, we modeled 
P(A|W) using the generalized additive framework (Hastie and Tibshirani, 1990) for a 
more flexible relationship between continuous covariates and response (Woo et al., 
2008).  Assuming a logistic additive model of the form      
        
        
     + 
   
 
       , where    (.),   (.),…,  (.), are smooth functions that defined the additive 
component, we computed the following expressions of probability: 
            
 
       
 
   
     
    
       
 
   
     
 and           
 
    
       
 
   
     
 .     
For continuous A, a flexible parametric approach, proposed by Irano and Imbens 
(2004) was used to compute a generalized propensity score.  First, we postulated a 
normal distribution of the continuous biomarker (A) given the covariates, i.e. 
             
 
 
     
  .  Then the parameters   ,   ,  
  were estimated by least 
squares regression.  Following Hirano and Imbens (2004), we estimated the 
generalized propensity scores by inserting the estimates of these parameters into the 
normal density:       
 
     
       
              
   
   .  
In the second stage of this approach, we created the weights. Stabilized weights 
for binary biomarkers A were computed as   
         
       
          
. For continuous 
biomarker variables, the estimated stabilized weights were constructed as a ratio of 
densities (i.e,       
   
     
) as proposed in Robins et al. (2000);     is the marginal 
density of the continuous biomarker (A), and        is the conditional density of the 
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biomarker (A) given the set of covariates (W). To estimate the numerator     we 
specified a normal distribution (i.e.           
   , and then substituted the mean 
    and the empirical variance   
   of the biomarker (A) values  into the normal 
density. The denominator was estimated based on the generalized propensity score 
method of Hirano and Imbens (2004) described above.  
Finally, the weights were incorporated into a logistic regression model to 
generate adjusted estimates. Separate estimates were created for each biomarker, 
and each logistic model contained binary CD4 as a dependent variable and the 
biomarker of interest and covariates as predictors.  All covariates used in the model 
were believed to be related to the outcome. 
2.3.6. Incremental Value Estimation for Partial Area Under the 
ROC Curve (pAUC)  
This method used the partial Area under the Receiver Characteristic Operating 
(ROC) Curve (AUC) methodology (McClish, 1989) while incorporating covariates in 
the analysis.  The goal was to assess the ability of each biomarker to discriminate 
above and beyond the set of covariates.   
Briefly, this method compared ROC curves for each combination of a given 
biomarker    and the covariates (W) to the ROC curve for the covariates (W) alone 
(McIntosh and Pepe, 2002; Janes and Pepe 2008; Janes, Longton and  Pepe, 2008).  
Each comparison assessed the amount of improvement in classification accuracy 
(incremental AUC) generated by adding the biomarker    to the covariates (W). The 
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basic assumption was that the covariates (W) contribute as well to discrimination 
between those with and without the outcome.  
Because the full AUC measure tends to lack clinical relevancy (Dodd and Pepe, 
2003; Obuchowski, 2005), we conducted this analysis at a false positive rate of 5% 
based on reports that the most common false positive rates of viral loads 
measurements often vary from 3% to 10% (Mendoza et al., 1998).  In terms of 
implementation, this procedure was accomplished in two steps: First, for each 
biomarker   , we estimated p(Y=1|A, W) and p(Y=1|W).  Using the predicted 
probabilities from the two fitted logistic models, we computed estimates of 
sensitivity and specificity over the restricted false positive range of 5%, and 
generated an index summary for the partial ROC Curve, referred to as pAUC. Finally, 
the measure of interest, the difference between the pAUC for the two models at 
hand, was computed. 
2.4. Data Analysis 
In the GS Study, the median age at enrollment was 27 years.  Women from 
Zimbabwe accounted for 58.5% of the population while those from Uganda made up 
the remaining 41.5%.  About 8% of all study subjects had at least two sex partners 
while 14% had a STI history, 8% were breastfeeding, and 45% displayed STI 
symptoms.  These women averaged 11.2 (Standard Deviation [SD] = 15.5) sex acts 
per month, but only 35% of them reported consistent condom use.  On average, the 
partners of these women spent 10 (SD=15.2) nights away from home, and 75% of 
those partners had been reported to have had sex with another woman in the three 
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months prior to enrollment in the study. Finally, 59% of the subjects’ partners met 
the study definition for primary partner risk, a composite variable that included 
having a partner with HIV, urethral discharge, weight loss, nights spent away from 
home, or a history of sex with female sex workers. 
The proportion of subjects with biomarker data available anytime from 
enrollment to 6 months after estimated infection date was as follows: 59% of the 306 
women had baseline CD4, CD8, and CD4/CD8 T cell ratio. The distribution of 
baseline CD4 cell counts was different in the two study countries.  On average, 
patients in Uganda had a higher level of baseline CD4 cell counts (650.72 
[SD=237.35]) than those in Zimbabwe (532.97 [SD=207.97]).  In addition, 79% of 
the study population had plasma viral load measurements while 56% had 
lymphocyte counts data. Finally, 58% of the 306 women had hemoglobin 
information, 98% had HSV data, and 97% had HIV sub-type information.  This 
proportion included 57 Zimbabweans imputed as subtype C based on the fact that all 
Zimbabweans with available subtype information were subtype C.  Overall, the 
majority of subjects were subtype C (59%), followed by subtype A (27%), and subtype 
D (11%).  Covariate information was available for all 306 subjects.  Subjects with 
missing baseline data for any biomarker were excluded from the analysis for that 
particular biomarker.  In addition, 23 subjects were removed from the analysis 
sample because their baseline CD4 cell counts were below 350 cells/ mm3. 
For each biomarker and under each method, we computed a variable 
importance measure and used bootstrapping for inference.  We conducted a separate 
hypothesis test of no effect for each biomarker.  In each case, the resulting p-value 
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was adjusted for multiplicity based on the Benjamini & Yekutieli dependent false 
discovery rate. Results under both the TMLE and the PSW did not support this 
hypothesis, as a number of biomarkers were deemed to have had a significant impact 
on the outcome (Table 1).  Based on the magnitude of the p-values, the most 
important biomarkers under the TMLE methodology, among the 11 biomarkers 
considered, were baseline CD4 cell count and CD4/CD8 T cell ratio.  Under the PSW 
approach, the biomarkers selected as the most important ones were: HSV-2 status, 
CD4/CD8 T cell ratio, baseline CD4 cell count, and Plasma Viral Load.  No 
biomarker was selected as important by the incremental value method. 
2.5. Simulation Studies 
 
We conducted simulation studies to evaluate the finite sample performance of the 
three proposed estimators.  The goal was to test the ability of each of these 
estimators to identify ―true‖ biomarker variables significantly related to an outcome.  
The simulated dataset consisted of a binary outcome Y, a 3-dimensional vector of 
continuous baseline covariates W=(W1, W2, W3), and a 5-dimensional vector of 
biomarkers A=(A1, A2, A3, A4, A5).  These variables were generated based on the 
following setup: 
a. The biomarkers were randomly assigned as: Pr(A1)=0.2, Pr(A2)=0.45, 
Pr(A3)=0.35, Pr(A4)=0.4, and Pr(A5)=0.5.  
b. Each baseline covariates followed a normal distribution: W1 ~(5,2), W2 
~(6,1.5), W3~N(0,1). 
c. The following model was postulated for the outcome:  
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                  , With        the inverse logit function, Aj the jth 
biomarker, and Wk the kth baseline covariate.  A larger coefficient for Aj did 
correspond to a larger effect on the outcome Y.  In this context, A2 and A3 
exerted a larger effect, while A1 had a moderate effect. 
Predicted probabilities generated from this model were compared against a 
uniform (0,1) random variable to create a binary outcome variable. For any 
record where the random variate was less than the predicted probability, a 
value of 1 was assigned to the outcome variable; else the outcome was 0.  
d. For each biomarker (A) and under each method, the simulation was run 5000 
times on increasing sample sizes of N=100, 150, 200, 250, and 1000. 
2.5.1. Simulation Results 
 
The simulation results (Tables 2-4) showed that all three estimators 
performed better with increasing sample sizes.  At N < 200, both the TMLE and the 
Propensity Score Weighting method picked up a single biomarker (A2) as significant.  
These two methods, although lacking power at that sample size level, did outperform 
the incremental value approach, which failed to detect any significant result.  At N ≥ 
200, all three methods correctly picked up biomarkers A2 and A3 as significant.  
This improvement in performance over increasing sample sizes is in accordance with 
previous simulation studies that assessed the finite sample properties of causal 
inference estimators such as G-Computation, IPTW, and Double robust estimators 
(Neugebauer and Van der Laan, 2005).  As for the ROC methodology, simulations by 
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Janes and Pepe (2006) did show a trend towards an increasing power of both full 
and partial of ROC curves in the presence of covariates as the sample size increases. 
Finally, it is worth noting that at N ≥ 1000 (results not shown), the weighted logistic 
method displayed slightly increased power as the proportion of rejected tests was 
higher than that of the other methods (three significant biomarkers detected by this 
approach as opposed to two biomarkers picked up by the other methods).  Based on 
its coefficient, the biomarker A3 could be considered to be moderately associated 
with the outcome Y, and the PSW method was powerful enough to detect this 
meaningful association.  
2.6. Discussion and Conclusion 
 
We compared three methods for estimating biomarker variable importance 
measures.  Our simulation results suggest that PSW works well in small sample sizes 
(say N> 100), but may be anticonservative when sample size is large (say, N> 1000).  
These results further indicate that TMLE could be a robust method that performs 
reasonably well in moderate to large sample size (say N≥150).  Finally, the 
incremental value approach displays an unsatisfactory ability in detecting significant 
biomarkers when the sample size is less than 200, but works satisfactorily with 
sample sizes exceeding 200. 
From a public health perspective, this research is relevant for the following 
reasons. It enabled us to identify from the GS study potentially useful candidate 
biomarkers based on their true importance with regards to the clinical outcome of 
CD4 cell count.  As a measure of a patient’s immune capacity, CD4 cell count has 
been considered as a standard method for determining eligibility for HAART and 
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HIV disease progression (Ellenberg, 1991; Fleming, 1994).  However, CD4 count 
measurements are expensive and could be prohibitive in resource-poor countries.  If, 
as our results indicate, baseline CD4 cell counts are highly predictive of future CD4 
cell count level, one strategy to both contain costs and save lives might be to obtain 
one initial  CD4 measure when infection is discovered, rather than having to do it 
repeatedly over time.  Furthermore, the list of biomarkers identified as important 
predictors of CD4 cell counts in this research, while in line with current medical 
knowledge, could also pave the way for the use of simpler and relatively less 
expensive biomarkers (e.g. CD4/CD8 T cell ratio) that are highly predictive of CD4 
cell decline and disease progression. This could support decision-making with 
regards to HAART initiation or could help monitor patients’ immune status during 
therapy without having to make additional expensive CD4 measurements.   
If is worth pointing out that the use of baseline CD4 to predict future levels of 
CD4 cell counts could raise the issue of circularity.  However, from a clinical 
standpoint, this could be a reasonable exercise because evaluation of baseline CD4 
cell counts could help identify patients at risk for CD4 cells depletion so that they 
could be monitored more closely and started on HAART, when necessary.  This could 
potentially help save lives, time, and money, especially in resources-deprived 
countries where the costs to measure CD4 are often prohibitive.  
This study does have limitations.  The two best performing methods (TMLE, 
PSW) rely on the assumption of no unmeasured confounders, i.e. within strata of 
covariates (W), the target biomarker (A) is randomized.  The thinking is that if the 
vector of covariates (W) contains all confounders, then among subjects sharing the 
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same W, the potential outcomes (  ,   ) and the biomarker (A) would be 
independent conditional on W (as would be the case in a blocked experiment where 
the treatment or biomarker (A) would be randomized within the levels of W) (Cole 
and Hernán, 2008; Schafer and Kang, 2008).  Given that the GS Study was 
observational in nature, exposure was not controlled, thus ―treatment‖ (i.e. 
biomarker) received might not be independent of potential outcomes.  In this case, 
the difference E {  |A=a} - E {  |A=0} might not be an unbiased estimate of the 
average treatment effect, as would be the case in a randomized study.  To account for 
this dependency, we tried to find all important covariates (W) believed to be related 
to both potential outcomes and exposure (A) based on the literature or expert 
knowledge, and included them in the estimation of the population average effect.  
There is no direct way to verify whether there remained any putative confounders 
that were not part of the vector of covariates (W) used in this study.  
Sample size could be another limitation of this study.  Over half of the biomarkers 
under consideration had 200 or fewer non-missing observations, with the minimum 
being 138.  As shown in our simulation studies, sample size does affect the ability of 
all three methods to detect ―true‖ significant biomarkers; all three showed a 
decreased ability in pinpointing significant biomarkers at smaller sample sizes (e.g. 
N=100).  Hence, sample size constraints may have hindered us from detecting 
additional significant biomarkers in the GS dataset.  The implication for applications 
is that, with small sample sizes, these methods may not achieve adequate power to 
detect the effect of a given biomarker.  Thus, strong consideration should be given to 
sample size and power issues when designing biomarker studies using these analytic 
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methods.  The sample size cut-points we identified through our simulations could 
serve as a starting point towards establishing sample size requirement guidelines for 
future data collection and assessment in biomarker studies where these selection 
methods are used. 
In summary, this study shows a promising practical application of both targeted 
maximum likelihood estimation and propensity score weighting to biomarker 
selection from observational studies.  Nonetheless, the list of significant biomarkers 
obtained varies with sample sizes, as demonstrated by our simulations.  For more 
conclusive results, future investigations, especially those involving the incremental 
value approach, should employ a much larger sample size.  Furthermore, we 
recommend that repeated measures analysis of longitudinal data be conducted to 
capture the trends and various dimensions of the CD4 count clinical outcome in its 
relationships with other HIV infection biomarkers. 
 
  
 
 
CHAPTER 3 
 
Application of Longitudinal Targeted Variable Importance Measures 
(LTVIM) to Biomarker Selection from an HIV Infection Dataset 
3.1. Introduction 
 
The past decade has seen an explosion in the availability and use of 
biomarkers data as a result of innovative discoveries and recent development of new 
biological and molecular techniques.  Biomarkers are essential for at least four key 
purposes in biomedical research and public health practice: They are used for 
disease detection, diagnosis, prognosis, to identify patients who are most likely to 
benefit from selected therapies, and to guide clinical decision making.  Determining 
the predictive and diagnostic value of these biomarkers, singly and in combination, 
is essential to their being used effectively, and this has spurred the development of 
new statistical methodology to assess the relationship between biomarkers and 
clinical outcomes. One such method aims at identifying biomarkers with good 
performance characteristics by computing a marginal variable importance measure 
(VIM) for each biomarker from a set, using the theory of targeted maximum 
likelihood estimation (TMLE) (Van der Laan, 2006). 
Much of the application of the targeted variable importance measure (TVIM) 
in literature deals with the simple case of point-treatment.  There is currently no 
unified approach to addressing VIM in the context of repeated measures data, even 
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though numerous studies dealing with biomarkers collect longitudinal data.  In this 
paper, we propose a novel approach to computing longitudinal VIM, when the 
interest lies in obtaining an estimate of the impact of a biomarker on the time course 
of a given clinical outcome.  This method extends the VIM computation based on the 
TMLE methodology to repeated measures longitudinal data, while taking advantage 
of the flexibility of a nonparametric smoothing technique.   The end result is an index 
that represents the strength of evidence for the importance of a biomarker with 
regards to a clinical outcome measured over time.  Inference for this estimator is 
readily available through bootstrapping. 
3.2. Statement of the problem 
Often in biomarker studies, researchers are faced with the task of evaluating 
the impact of multiple biomarkers on a given outcome.  Given a large set of 
biomarkers that potentially predict a clinical outcome, how can one make a 
determination as to which ones are the most important?  Answers to this question 
are of great practical importance to public health practice and pharmaceutical 
research.  Statistical methodologies that allow  researchers to take a pool of 
biomarkers and make a reliable appraisal as to which ones are the most important, 
could lead to faster decision making in epidemiologic studies and clinical trials.  For 
instance, an effective and efficient selection of the best subset of biomarkers amongst 
a set could help direct further biological research in early phases of clinical trials by 
limiting the focus to the pool of most promising ones.  From a scientific standpoint, 
this could guide statistical research in the area of biomarker validation by making 
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available a list of good candidates for surrogacy status determination.  Such a list 
could also be useful in the quest for the best combinations of biomarkers. 
In this study, we address the issue of biomarker selection in the context of 
longitudinal repeated measures data.  The outline of the paper is as follows.  Sections 
3.3 and 3.4 review the theory of targeted maximum likelihood estimation and 
provide the implementation steps for two estimators of interest.  Section 3.5 
describes an HIV infection dataset used to illustrate these estimators while section 
3.6 reports on the analysis and results.   Section 3.7 covers a Monte Carlo simulation 
to study the behavior of these two estimators under different numbers of repeated 
measures.  Finally, section 3.8 provides a discussion of the results and ideas for 
further research. 
3.3. Targeted Maximum Likelihood for Variable Importance 
Measure 
 
To facilitate the discussion of the methods, we let the observed data be 
represented by O= (A, W, Y(t)) where A represents a set of either binary or 
continuous biomarker variables, W a vector of covariates, and Y(t), a time-varying 
clinical outcome.  Define the observed data as              ,  the counterfactual 
outcomes of interest as   , and the full data as  
        , a   A), where a=(0,1) 
(binary case) or A   ={               (continuous case).  For simplicity, we assume 
that both A and W are static. 
In order to select the most important biomarkers (A) affecting the outcome 
(Y(t)),  we used a tool named targeted maximum likelihood estimation (Van der Laan 
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and Rubin, 2006). The TMLE is a versatile method suitable for parameter estimation 
in semi-parametric and nonparametric models from either randomized or 
observational studies.  It could be used in a variety of settings: cross-sectional, 
repeated measures longitudinal, and time-to-events.  In this study, we applied this 
technique to generate a marginal variable importance measure that captures the 
impact of each biomarker on the clinical outcome. 
Our choice of this estimation method is motivated by its attractive statistical 
properties: adequate bias-variance tradeoff, efficiency, consistency, robustness.    
Theoretical and simulation studies have shown that the TMLE provides higher 
precision and reliability than other methods such as random forests, neural 
networks, least angle regression, univariate regression (Tuglus et al., 2008).  
Furthermore, the TMLE estimator could be, under certain conditions, a doubly 
robust measure that could also be free from standard regression model assumptions.  
By using information from two conditional distributions, namely the outcome model 
(e.g. E[Y(t)|A,W]), E denotes expectation), and the treatment mechanism ( e.g 
(E[A|W]), the TMLE produces consistent estimates as long as one of these two 
nuisance parameters is correctly estimated (Bembom et al, 2008; Rosenblum and 
van der Laan, 2010).   Because of this property, referred to as double robustness, the 
TMLE presents a notable advantage, especially in situations where it might be easier 
to correctly specify the relationship of the biomarker with covariates or in situations 
where it may be easier to model the relationship between the clinical outcome and 
the biomarker and covariates.  Overall, this approach presents a clear advantage over 
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conventional estimation methods whenever concerns linger about the correct 
specification of either E[Y(t)|A,W]) or E[A|W]. 
For a formal and theoretical discussion of the TMLE, the interested reader is 
directed to Van der Laan and Rubin (2006), Van der Laan et al. (2009).  Empirical 
examples or applications of the TMLE in biomarker selection are given in Bembom 
et al. (2008), Tuglus and Van der Laan (2008), Moore and Van der Laan (2007), and 
in Rosenblaum and Van der Laan (2010).  
3.3.1. Measure of Effect 
 
In this study, we pick as a meaningful measure of effect, for each biomarker, 
the targeted marginal mean.  It is defined as the difference in probabilities between 
those with and without the biomarker exposure of interest (A=1 vs A=0), averaged 
over the entire population, at time t, i.e   (t)=   [E(Y(t)|   =1, W) - E(Y(t)|   =0, 
W)]. In the continuous case, the parameter of interest was given by  (t)=   [E(Y(t)| 
  =a, W) - E(Y(t)|   =  , W)], (   refers to the empirical means of the biomarker 
measurements). 
The TMLE is done in the context of potential outcomes or counterfactual 
framework.  Essentially, each subject in the sample is assumed to have potential 
outcomes in two states, the one in which the subject is observed and the one in which 
the subject is not observed (Winship and Morgan, 1999).  This potential outcomes 
framework allows one to estimate the unobservable difference for each subject 
between outcomes under both conditions.  For more detailed technical discussions 
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and applications of counterfactuals, see Robins et al (2000), Winship and Morgan 
(1999); Winship and Sobel (2004). 
3.3.2. TMLE Implementation 
We followed a three-step approach to implement the TMLE methodology.  First, 
we applied the generalized estimating equations (GEE) framework (Liang and 
Zieger, 1986; Zeger and Liang, 1986) to model the conditional distribution of Y(t) 
given A and W, i.e.             . Note that, in this first step, the risk of model 
misspecification could be mitigated by using a variety or combination of techniques, 
including data adaptive procedures, to arrive at a suitable functional form.  For 
example, when Y(t) is binary, we fit the model g[E(Y(t)|W, A)] =         
     
 
 , where g [.] is a logistic function.  Predicted probabilities from this outcome 
model were denoted by    (A,W).   Next, we estimated the conditional distribution of 
the biomarker given the covariates,       .  For binary biomarkers A, the estimates 
of the probabilities  (  =1| W) and  (  =0| W), denoted by   
  (A, W), were used to 
calculate a specific covariate h(A,W) as follows:          
      
  
       
  
      
  
       
 ).  For 
continuous biomarker (A), we followed Tuglus et al. (2008) and defined the 
covariate h(A, W) as:                  
 The next stage in applying the TMLE entailed updating the initial estimate 
  (A,W) with the covariate h(A,W) by regressing the binary outcome Y on the 
covariate h(A,W) in an intercept-only model where the initial estimates    (A,W) 
were held fixed. Specifically, the updated estimate   (A,W) is given by 
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  (A,W)=(A,W)=  (A,W) + (         .  The regression coefficient   is obtained 
through maximum likelihood estimation (MLE) using    (A,W) as offset. From this 
regression, we obtained the maximum likelihood estimate   for the covariate h(A,W) 
and used   to update the  initial estimate of   (A,W) such that    (A,W)=   (A,W) + 
(             Finally, we computed the targeted estimate of the marginal variable 
importance measure of interest, for each binary biomarker, by evaluating   (A,W) at 
both   =1 and   =0 for  each individual i, and then averaging over all i.  For 
continuous biomarkers,   (A,W) was evaluated at both   =a and   =   . These steps 
were repeated for each biomarker, and the end result was an estimate of the variable 
importance of each biomarker at each time point, i.e.   (t) at time t=0, 1, 2,…n. 
3.4. Longitudinal Summary Index Measures 
 
 Our goal is to provide a summary measure over time instead of a visit by visit 
analysis.  In the next section, we consider two estimators for computing a scalar 
value denoting the importance of a given biomarker over time.  We refer to this index 
as longitudinal  targeted variable importance measure (LTVIM).    
3.4.1. Time Slope from Regression through the Origin 
 
 Assuming that the targeted variable importance measure (TVIM), as applied 
above, is close to 0 at time 0, this approach consists in fitting a no-intercept 
regression model with the TVIM as dependent variable and time as independent 
variable (Bembom et al, 2006).  Since the data are made of a sequence of VIM data 
points at successive times, the regression errors may not be independent of each 
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other through time.  To account for autocorrelation in the residual series, we fit a 
model where the errors are assumed to follow the first order autoregressive process.  
This model postulates an autocorrelation that diminishes rapidly as the distance 
between the times points increases.  It takes the form:               , where the 
random residual      -      ,           
 ), and       .  In this model,    (a 
residual called white noise) is assumed to be uncorrelated with other residual 
components, and    determines the sign and strength of the autocorrelation.  The 
use of the subscript t emphasizes the fact that the data are taken over time. 
 Estimation of the parameters of the model (   and     is performed through 
maximum likelihood, and the measure of impact for each biomarker is given by     .  
A biomarker with a positive impact over time would have a positive coefficient     
while a negative sign of the coefficient would translate a negative effect.  Inference 
can be made by using bootstrapping to construct standard error for the test of the 
null hypothesis:      for each biomarker.  
 3.4.2. Area under the LOESS Curve. 
 
 Consistent estimate of the slope parameter in the auto-regressive model above 
relies on proper specification of the deterministic component (i.e. E(      , E 
denotes expectation), and of the residual component   .  Furthermore the white 
noise residual    is assumed to satisfy all the classical assumptions (normality, 
independence, homoscedasticity).  Those assumptions may not always be tenable.  
For instance, the true relationship between TVIM and time may be curvilinear. In 
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such case, having a straight line forced through the origin may not always provide a 
good approximation to the mean response E(TVIM). 
 One way to relax the assumptions about how the TVIM changes as a function of 
time would be to implement data-adaptive techniques.  One such approach proposed 
in Bembom et al (2006) for fitting the regression is the 
Deletion/Substitution/Addition (D/S/A) algorithm (Sinisi, 2004).  In this paper, we 
propose an alternative approach based on nonparametric regression.  It consists in 
plotting the estimated variable importance,  (t), as a function of time, using the 
locally weighted scatterplot smoothing technique (LOESS) (Cleveland, 1979; 
Cleveland and Devlin, 1988).  In short, this method works by moving a window along 
the time-axis, computes a fitted value at each position in the window and then 
connects the predicted values to generate the LOESS curve. This method is highly 
flexible as it requires no specification of a parametric model.  The only inputs needed 
are a smoothing parameter (usually between 0 and 1) and the degree of the local 
polynomial (usually 1 or 2) to be fitted to the data. 
 Using the predicted values from the LOESS function, we compute, as our 
longitudinal summary measure of variable importance, the area enclosed by the 
LOESS curve and the time axis.  Based on the composite Simpson’s rule for 
numerical integration, the index measure of interest is given by:  
           
 
 
 
 
 
              
  
 
         
  
 
         
 
   
   
     where the 
time interval [a, b] is subdivided into 2m subintervals                  
   of equal 
width    
   
  
 . Because the TVIM could be negative, we take as the final measure of 
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impact the absolute value of the area under the LOESS curve, which means that a 
TVIM of -0.5 is equivalent to a TVIM of 0.5.   What matters here is the magnitude of 
the effect, not its direction. 
3.4.3. Bootstrapping Algorithm and Multiple Comparison 
To generate standard errors for the estimates of the LTVIM measures 
obtained under each method, bootstrapping (Efron and Tibshirani, 1994) was 
implemented.  We applied the following algorithm for bootstrap selection and for 
assessing multiple comparison: 
1. From the original sample S, we drew B independent bootstrap samples 
            , each of size n, assuming simple random sampling with 
replacement. 
2. For each bootstrap sample, we then computed the sample quantity of 
interest     (Under the Regression through the origin method,     refers 
to the estimated time slope; in the LOESS method,     is the estimated 
area under the LOESS curve).  This resulted into B values of the 
statistic    . 
3. The bootstrap estimator of the parameter   was given as the mean of 
the bootstrap estimates    
   =
 
 
    
 
   , with variance   (     
 
 
 
         
         .  The standard deviation of the distribution of the 
statistic     was then:          = 
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4. We subsequently assessed the strength of the evidence for a non-zero effect 
by conducting the following test of hypothesis:          versus         
      , for each j (j=1,…, k).  In the LOESS-based method, we conducted a one-
tailed test of hypothesis:          versus          
5. We repeated these steps k times, that is once for each biomarker       
1,……k to generate k estimates of    and k p-values denoted as P1, P2,…, Pk. 
6. Finally, we adjusted the p-values for multiplicity testing to control the false 
discovery rate.  The Benjamini and Yekutieli (2001) False Discovery Rate 
(FDR) controlling procedure was used to account for the dependence of the 
test statistics.  Significance for each biomarker was assessed by comparing 
related adjusted p-value to the 0.05 alpha level. 
3.5. Genital Shedding and HIV Infection (GS ) Data Description 
 
The dataset used for application in this paper came from the Hormonal 
Contraception and HIV Genital Shedding and Disease Progression or GS Study.  The 
GS Study is a prospective multicenter study of 306 HIV infected women aged 18 to 
45 years old from Uganda and Zimbabwe.  This study started in 2001 as an add-on to 
the HC-HIV study (Morrison et al., 2007) and was completed in the field in 
December 2009.  Women who seroconverted during the course of the HC-HIV study 
were recruited for the GS study, based on procedures outlined in Morrison et al. 
(2010). The study specific objectives are described in details elsewhere (Morrison et 
al., 2007, 2010), but one key research question is the effect of hormonal 
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contraception on the biological parameters of the infectivity of women with primary 
and chronic HIV infection to their sex partners. 
The GS Study consisted of a baseline visit and follow-up visits at 2, 4, 8 and 12 
following HIV seroconversion, and then every 12 weeks for up to 9 years.  Women 
who developed severe HIV infection or who had successive CD4 cell counts at or 
below 200 cells per mm3 were offered highly active antiretroviral therapy (HAART) 
and were seen twice a month for the first month, then monthly thereafter.  In 
addition to baseline demographic characteristics, information on various laboratory 
parameters, reproductive variables, contraceptive exposure, and recent sexual 
behavior was collected at each study visit.  Gathered laboratory data included HIV 
plasma viral load, HIV sub-type, CD4, CD8 and total lymphocyte counts, serum 
chemistries, lipid profile,  and specimens for the detection of chlamydial, gonococcal, 
syphilis, herpes simplex virus 2 (HSV-2), and Human papillomavirus (HPV) 
infections.  The study also collected information on hormonal contraceptive use, HIV 
disease progression parameters, as well as virologic, immunologic, and clinical 
response to HAART among hormonal and non-hormonal contraceptive method 
users. For a detailed description of the study population and procedures, the reader 
is directed to Morrison et al. (2010).        
3.5.1.  Outcome Definition 
 
In this analysis, the binary clinical outcome, Y(t),  was defined as a drop in 
CD4 cell counts below 350 cells/mm3 at time t.  The choice of the threshold of 350 
cells per mm3 for the clinical outcome of CD4 was based on current guidelines for the 
use of antiretroviral agents in adults and adolescents infected with HIV-1 in the 
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absence of an AIDS-defining illness (Panel on Antiretroviral Guidelines for Adults 
and Adolescents, 2008; Hammer et al., 2008). Also, evidence from the literature 
suggests that initiation of antiretroviral therapy before the CD4 cell counts falls 
below 350 cells per mm3 significantly improves survival, as compared to deferred 
therapy (Sax and Baden, 2009; Kitahata et al., 2009; When to Start Consortium, 
2009).  
3.5.2.  Biomarker Variables and Covariates   
                                                                                        
The set of covariates (W) used in this analysis consist mainly of behavioral, 
reproductive, and demographic factors reported in the literature to be predictive of 
incident HIV infection or clinically associated with HIV disease progression (Van 
Der Pol et al., 2008).  These covariates included age, country, number of coital acts 
in previous 3 months, condom use consistency, study subject’s partner’s sexual 
behavior and risk, frequency of  nights away from home by study subject’s partner, 
history of sexually transmitted infections (STI), presence of STI symptoms at 
enrollment, having more than one sex partner, and breastfeeding.  The vector of 
biomarkers A contained measures such as plasma viral load, HIV sub-type, 
hemoglobin level, CD4, CD8  and lymphocyte counts, CD4/CD8 T cell ratio, CD4 
percentage, HSV-2 status. While HIV sub-type and HSV-2 status were binary 
variables, all other biomarkers used in this analysis were measured on a continuous 
scale. 
3.6. Data Analysis 
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We carried out a set of separate analyses to estimate the effect of each 
biomarker on the mean outcome over time, adjusting for covariates.  First, we 
implemented the TMLE methodology to produce a TVIM at each time point. As 
described above, we generated two nuisance parameters, namely E[Y(t)|A,W] and 
E(A|W).  To model E(Y(t)|A,W), we specified the following logistic mean model: 
                                                             
  
    , where 
   represents the target biomarker variable,         the measurement occasion for 
subject i  at time j,  and    , the vector of covariates listed in section 4. We further 
specified the variance as Var(   )=V(                , where     and      
 
          
             
.  Finally, we assumed that the correlation between measurements     and 
    taken on subject i at times     and    had an exchangeable structure.  
From this model, we extracted the predicted values, which were subsequently 
updated  with a covariate constructed from another nuisance parameter, E(A|W).  In 
our application, the systematic component (    that described the effect of the 
covariates (W) on the expected value of the biomarker (A) was given by:    
       
 
 
             
 
   , where g(.) was assumed to be a logit link for binary 
biomarkers (0 <  <1), and an identity link for continuous biomarkers.  The    s are 
all listed in section 4. 
Once the TVIM was obtained, it was regressed over time to obtain the 
longitudinal measure of importance based on the regression through the origin 
method.  We also took a second approach to analyzing the data by using smoothing 
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to highlight trends and patterns in the data.  For each biomarker, we fit a smooth 
curve to the pair (TVIM, TIME) to produce a smooth estimate of the function, which 
is then used to compute the area under the LOESS curve based on a smoothing 
parameter of 2/3 and a local polynomial of degree 1.  To mitigate the influence of 
outliers, we used the ―symmetric‖ family option of the LOESS function from the 
STATS package in R (version 2.7.2).  This option combines the local fitting with a 
robustness step that downweights the relatively large residuals from the fitted curve.  
This robust smoothing allows for a better extraction of signal from noise.   
3.6.1. Results 
 
The GS study sample included 306 subjects followed up to 9 years.  Of those, 
23 subjects were excluded from the analysis because their baseline CD4 cell counts 
were below 350 cells/mm3. Any subject who was given HAART therapy was censored 
at the time of HAART initiation and contributed data to the analysis up to the most 
recent date preceding HAART initiation. 
For each biomarker and under each method, we computed a variable 
importance measure and used bootstrapping for inference.  We conducted a separate 
hypothesis test of no effect for each biomarker.  In each case, the resulting p-value 
was adjusted for multiplicity based on the Benjamini & Yekutieli dependent false 
discovery rate.  Results obtained under the two methods under consideration are 
reported in Table 5.  Among the 11 biomarkers, the ones selected as the most 
important based on the magnitude of the p-values, are baseline CD4 cell counts, HIV 
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subtype, and HSV-2 status. This list was consistent across the two analytic methods 
highlighted in this paper.  
A useful piece of information that could be extracted from a visual inspection 
of the LOESS plots in Figures 2 & 3 is an assessment of the longevity of the 
biomarkers in terms of their predictive power.  For instance the predictive power of 
baseline CD4 cell counts reached its peak around visit 15 and then the LOESS curve 
displayed a steady decline, suggesting a slowing of the impact of this biomarker on 
the clinical outcome over time.  For a number of biomarkers (i.e. subtype A and D, 
CD4 percent, CD4/CD8 T-cell ratio, HSV-2), the downward pattern started early and 
continued over the entire study period.  Finally, there was no detectable relationship 
between VIM and time for CD8 cell counts, hemoglobin, HIV RNA, lymphocyte 
counts, and Hemoglobin level.. For these biomarkers, the LOESS smoother relating 
VIM trend to time was mostly a flat line aroud 0 (figure 2).   
3.7. Simulation 
 
We conducted a simulation to assess the performance of the two proposed 
estimators.  The ultimate goal was to test the ability of each of the two estimators to 
identify ―true‖ biomarker variables significantly related to a given outcome, based on 
different scenarios for the number of data points (i.e. number of repeated measures 
in the study design). Because we were primarily interested in evaluating how the two 
methods performed in selecting biomarkers based on the relationship between  a 
continuous TVIM variable  and time, we created a simulated dataset that contained 
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only these two variables.   Thus, the scope of this simulation was limited in testing 
and quantifying the effect of the independent variable time on VIM. 
We postulated the following regression model to describe the relationship 
between time and VIM:                      
   , Where               
We assigned the following values to the regression coefficients:   =4.17,   =0.06, 
and   =-0.002. The rationale for the choice of a model with curvature was two-fold.  
First, most real-life applications do not involve a straight line going through the 
origin, and may entail some degree of curvature.  Second, such a model would allow 
us to assess the robustness of the first order autoregressive model with respect to 
violation of the linearity assumption. 
 Simulated data points were generated according to the number of measurements 
taken over the span of the study, and there was one VIM observation per 
measurement.  Thus, if 10 measurements were taken on each subject, then the 
number of observations used in the regression model would be 10, regardless of the 
number of subjects, because the VIM, as defined above, is a summary measure of the 
importance of a given biomarker at each time point.  We then evaluated the impact 
of time on VIM based on the following scenarios for the number of measurements: 5, 
10, 20, and 25.  In each case, we computed the two estimators, based on 5000 
bootstrapped estimates.   The results are presented in Table 6. 
3.7.1. Simulation Results 
 
At n=5, both methods failed to detect a significant relationship between time 
and TVIM. The LOESS-based method performs satisfactorily for sample sizes >=10, 
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while the autoregressive model detects significant relationship between time and 
VIM only when n >=20. These results indicate that the intensity of the effect of the 
biomarker, as measured by decreasing p-values, is better captured with increasing 
number of repeated measurements. 
3.8. Discussion and Conclusion 
 
In this paper, we highlighted two methods to generate an index measure that 
captures the impact of a biomarker on a clinical outcome, in the longitudinal 
repeated measures setting.   Both approaches constitute an extension of the theory of 
targeted maximum likelihood estimation.  While the time slope method is simple 
and easy to implement, it is not free from standard regression models assumptions.   
Simulation results show that its performance could be constrained when the number 
of repeated measures is less than 20. 
    In the LOESS method, no strong global assumptions are needed about the 
conditional mean of the VIM, and no specific functional form is assumed.   Results of 
the analysis of the GS data as well as the simulation reported in this paper confirm 
that this method produces results that are at least as good as those from the time 
slope method.  One improvement over the time slope approach is that the LOESS 
method provides insight into the longevity of the predictive power of a given 
biomarker.  From the LOESS plots, one can readily assess which biomarkers predict 
the outcome early or late in the process, how far ahead in time a biomarker measure 
could predict a clinical outcome, and whether and when the effects of a given 
exposure start to wane.  This could have practical implications: study investigators 
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could use this kind of information to decide when the optimal time to take repeated 
measurements of a biomarker would be.  This could help reduce waste and improve 
compliance issues as repeated measurements would be taken only when they are 
needed. 
From a public health perspective, this research is relevant for several reasons. 
It enabled us to identify from the GS  study potentially useful candidate biomarkers 
based on their true importance with regards to the clinical outcome of CD4 cell 
count.  Our results indicate that useful predictors of CD4 cell counts are:  HIV 
subtype, HSV-2 status, and baseline CD4 cell counts. This list seems to be in line 
with current medical knowledge.  For instance, studies by Kanki et al. (1999) and by 
Kaleebu et al (2000, 2002) have shown that the HIV-1 subtype an individual 
becomes infected with can be an important factor in the rate of disease progression.  
With respect to subtype, the results of this analysis should be interpreted in the 
African context, where the subtypes under study are the most prevalent.  These 
results may not be applicable to Western developed countries where subtype B is 
largely dominant. 
As a measure of a patient’s immune capacity, CD4 cell count has been 
considered as a standard method for determining eligibility for HAART and HIV 
disease progression (Ellenberg, 1991; Fleming, 1994).  However, CD4 count 
measurements are expensive and could be prohibitive in resource-poor countries.  If, 
as our results indicate, baseline CD4 cell counts are highly predictive of future CD4 
cell count level, one strategy to both contain costs and save lives might be to obtain 
one initial  CD4 measure when infection is discovered, rather than having to do it 
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repeatedly over time.  In the event that other repeated measures of CD4 cell counts 
are needed, one might be able to limit the frequency of these measurements by using 
the LOESS method outlined in this paper. 
This study does have limitations.  The TMLE method relies on the assumption 
of no unmeasured confounders, i.e. within strata of covariates (W), the target 
biomarker (A) is randomized.  The thinking is that if the vector of covariates (W) 
contains all confounders, then among subjects sharing the same W, the potential 
outcomes    and the biomarker (A) would be independent conditional on W ( As 
would be the case in a blocked experiment where the treatment or biomarker (A) 
would be randomized within the levels of W) (Cole and Hernán, 2008; Schafer and 
Kang, 2008).  Given that the GS  study was observational, exposure was not 
controlled, thus ―treatment‖ (i.e. biomarker) received might not be independent of 
potential outcomes.  In this case, the difference E {  |A=a} - E {  |A=0} might not be 
an unbiased estimate of the average treatment effect, as would be the case in a 
randomized study.  To account for this, we tried to find all important covariates (W), 
believed to be related to both potential outcomes and exposure (A) based on the 
literature or expert knowledge, and we included them in the estimation of the 
population average effect.  There is no way to verify whether there remained any 
putative confounders that were not part of the vector of covariates (W) used in this 
study.  
Another limitation is inherent to the LOESS procedure.  If the data do not 
have a monotonic progression, the LOESS curve may not be an effective tool in 
differentiating signal from noise.  If there are too many peaks and valleys, or up and 
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down patterns, the LOESS method may display inability to tease out true biomarker 
effects from noise.  Moreover, LOESS works better on large and densely sample 
datasets, which could hinder its usefulness in studies where the number of 
measurements is relatively small.  Our simulation study has shown that the two 
estimators have poor performance when the number of repeated measures is 5 or 
less.  Because of this shortcoming, there may  be little value in using these methods 
when the number of data points ( i.e. repeated measures) is fewer than 10.   They 
could be more suitable to longitudinal studies with extensive data collection over 
many time points.  One extreme example could be the reported trial of a topical 
treatment for HIV-related peripheral neuropathy where patients were required to 
record pain four times a day for four weeks at baseline and at follow-up, for a total of 
224 data points (Paice et al, 2000). 
In summary, this study shows a promising practical application of the 
targeted maximum likelihood estimation to generate a longitudinal variable 
importance measure for each biomarker from a set.  In this research, both 
biomarkers and covariates were chosen at 6 months from estimated infection date.  
One future area of research could be the inclusion of time-varying biomarkers and 
covariates. It is possible that some biomarkers would exhibit a significant effect on 
CD4 cell count only when they are allowed to vary over time.  In such situations, the 
measure taken at baseline (in this application, at viral load set point) may not be a 
good predictor of the outcome over the long term.  As a future direction, we would 
also recommend taking censoring into consideration, by applying the TMLE 
methodology in a time to events setting.
  
 
 
CHAPTER 4 
Inverse Probability Weighting to Estimate Biomarker Variable 
Importance Measures from an Observational HIV Infection Dataset 
4.1. Introduction 
Biomarker identification related to many clinical and health outcomes is a 
focus of tremendous research activity on many levels, from basic laboratory studies 
through epidemiological investigations and late phases of clinical trials.  Biomarker 
data are often used for disease detection, diagnosis, prognosis, to identify patients 
who are most likely to benefit from selected therapies, and to guide clinical decision 
making.  Due to major advances in technology and in modern biology, a large 
number of biomarkers have been identified, and selection of the ones with maximal 
impact on clinical outcomes has become a critical issue.  This has given rise to a 
quest for novel statistical methods that could adequately explain the relationship 
between biomarkers and outcomes of interest.  This paper applies an innovative 
methodology, the inverse probability weighting, to the issue of biomarker 
identification in the presence of fixed covariates, in the time to events setting. 
In biomarker studies involving longitudinal time to event analysis, a 
reasonable goal could be to estimate the importance of each biomarker from a set 
with respect to the time it takes for a clinical event to occur.  A standard analytical 
approach to estimating biomarker variable importance in relation to survival 
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consists in fitting a Cox proportional hazards model with all measured covariates 
and then computing the measure of effect of interest.  This approach, however, may 
produce biased estimates of the exposure effect if the censoring mechanisms are 
non-random (i.e. informative) (Robins, 1995).  For instance, in the analysis of the 
effect of HIV infection biomarkers on CD4 cell counts, both loss to follow-up 
(depending on the reason) and death could lead to informative censoring, as they 
might be associated with the CD4 cell  value at the time of the event.  An example of 
such occurrence can be found in Touloumi et al (1999).  In their comparison of  CD4 
cell count trends between subjects with low (L) and high (H) doses of didanosine 
(ddI) in patients with symptomatic HIV disease intolerant to zidovudine (AZT), 
using data from the Alpha Trial, Touloumi and his colleagues found that drop-outs 
due to death occurred more frequently in subjects with low CD4 cell counts.  In this 
case, because the probability of drop-out was associated with the value of the 
previous CD4 cell count, the censoring mechanism was informative; for this reason, 
the use of standard analytic methods could lead to overestimation of exposure effects 
because subjects with worse CD4 count evolutions would have shorter follow-up 
times and hence would be weighted less in the estimations of the group rate of the 
average CD4 cell counts decline (Duvignac  and Thiébaut, 2006).   
One strategy for dealing with the bias arising from either confounding or 
informative censoring is through the use of inverse probability weighting, whereby a 
weight is attributed to the contribution of each subject i to the risk set at time t.   This 
estimator exploits available auxiliary information to control for confounding through 
an exposure assignment process and adjusts for differential drop-out and 
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informative censoring via a censoring mechanism. The idea of weighting originates 
from the survey sampling field where subjects from a given sample are weighted by 
the inverse of their probability selection to ensure adequate representation of the 
population in which samples were drawn (Kish, 1965, 1990).  In observational 
studies, there is no random allocation of exposure, and thus, subjects with certain 
baseline prognostic factors may be either over-represented or under-represented in 
certain exposure groups. Because observed differences in observational data may 
reflect underlying differences between groups, it is critical to mitigate bias resulting 
from the imbalance in covariate distributions.  Similar situation occurs in event 
history data with differential attrition and censoring.  To deal with this bias, Robins 
(1999, 2000) proposed a weighting scheme referred to as inverse probability of 
treatment weighting (IPTW). 
The basic idea in using the IPTW estimator is to create a re-weighted dataset 
in which a balance is achieved in the distribution of covariates between exposure 
groups, as would be the case in a randomized intervention.  Implementation of this 
approach involves fitting a multivariate regression of the probability of the exposure 
given covariates.  This model, referred to as the treatment mechanism, is used to 
compute propensity scores or the conditional probability of receiving one’s own 
exposure given a vector of observed covariates (Rosenbaum and Rubin, 1983).  
Letting    be the probability of a subject receiving the exposure actually received 
conditional on observed covariates (i.e. propensity scores), unstabilized weights 
(denoted by   ) are given by  
 
  
 for exposed subjects, and by 
 
    
 for unexposed 
subjects.  Thus, subjects with low probability of exposure are assigned relatively 
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larger weights while those with common exposure status given covariates are 
attributed lower weights.  According to Robins and colleagues (2000), weighting 
creates a pseudo-population made of    copies of each subject i.  For instance, a 
subject with       would contribute 10 copies of himself to the pseudo-population 
to make up for subjects with similar characteristics that have not been observed.   In 
this pseudo-population, exposure is no longer confounded by covariates because 
outcome and exposure are conditionally independent given the covariates.  
Therefore, analysis performed on this re-weighted population could generate 
unbiased estimates of the exposure effect (Robins et al, 2000). 
Unstabilized weights may suffer from a shortcoming whenever the set of covariates 
used are strongly associated with the exposure, especially in non-saturated models.  
In such occurrences, the weights might have large variability, which could result, 
according to Robins (2000), in a few subjects having extremely large values of the 
weights   ; these subjects could  dominate the weighted analysis because of the large 
number of copies of themselves they contribute to the pseudo-population relative to 
the contribution of other subjects.  Studies by Kang and Schaffer (2007) have shown 
how unstable weights could result in a poor performance of the IPTW estimator.   A 
solution proposed by Robins (2000) has been to use stabilized weights (designated 
by       instead, where some function of the exposure is used as the numerator of the 
weights instead of 1 (Robins et al, 2000).  A common practice has been to use the 
sample proportion of subjects with the exposure (A) of interest (i.e.  p(A=a)) to 
stabilize the weights, as was done in Cole and Hernán (2004). Thus, if an exposure 
(A) and a set of covariates (W) were unconfounded, the numerator and the 
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denominator of the stabilized weights would be the same (i.e.  p(A=a) =P(A=a|W)), 
resulting in a     of 1.  All subjects with       would then contribute the same 
weight to the risk set.  
An indication of well-behaved weights is a mean of 1 (or in the neighborhood 
of 1) with a relatively small variability.  A mean of 1 for the weights is often viewed as 
a necessary condition for correct model specification (Hernán and Robins, 2006; 
Cole and Hernán, 2008); however, near-perfect weights (with mean of 1 and a small 
range) may have no effect on the parameters of the Cox regression model, as they fail 
to control for confounding (Cole and Hernán, 2008). Conversely, weights with mean 
far from 1 or with extreme values may be symptomatic of violation of the 
assumptions used in the estimation of the weights.  
The concept of weighting has been extended to studies involving censoring 
(Robins et al, 2000; Hernan et al, 2000) through the inverse probability of 
treatment and censoring (IPTC) estimator.  The basic idea remains the same: exploit 
available auxiliary information through a weighting scheme to control for selection 
bias arising from differential drop-out and informative censoring. The censoring 
weights are estimated in an analogous way to the exposure weights except that a 
censoring indicator is now used as the dependent variable while exposure is an 
added as an additional regressor in the multivariate regression model.  The 
censoring weight is the inverse of the probability of a patient i remaining uncensored 
up to time t.  As in the case of the exposure weights, it is a good practice to stabilize 
the censoring weights as well.  Finally, each subject’s contribution to the risk set at 
time t is weighted by the product of the exposure and censoring weights (Robins et 
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al, 2000; Hernan et al, 2000).  Application of a Cox proportional hazards model - or 
the equivalent pooled logistic regression model - to this weighted population 
generates consistent estimates of the exposure effect (Robins et al, 2000; Hernán et 
al., 2000, 2001) because the weights adjust for all measured confounders, which 
allows one to fit an association model on a dataset where selection bias has been 
removed.   
The outline of the paper is as follows.  Sections 4.2 reviews a weighted Cox 
proportional hazards model proposed for biomarker selection.  Section 4.3 describes 
an HIV infection dataset used to illustrate the appropriateness of this modeling 
framework to the problem of biomarker selection using survival data.  Section 4.4 
reports on the analysis and results.   Section 4.5 discusses the results while Section 
4.6 concludes and provides ideas for future research. 
4.2. Materials and Methods 
4.2.1.  Statistical Model 
 
The goal of the analysis was to estimate a variable importance measure that 
reliably captures the marginal effect of  a set of HIV infection biomarkers on the time 
to the clinical event of interest (as defined in section 4.3).  To fix notation, let     
denote the failure time of interest and     the censoring time for the ith subject in the 
sample.  Furthermore, let                 be the observed time response variable, 
and               the censoring indicator such that   =1 if the response was 
censored, and 0 otherwise.  Finally, let’s assume there are p exogenous covariates 
  = (   ,   , . . . ,   ) , and j biomarkers   = (   ,    , . . . ,    ), recorded for each 
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subject i at baseline.  The right censoring data structure is thus given by O =(       , 
  ,    .   
In the traditional framework of the Cox proportional hazards model (Cox, 1972), the 
regression model for the hazard as a function of a biomarker (A) and p exogenous 
covariates can be specified as the product of a baseline hazard and an exponential of  
the linear function of A and the W’s.  More specifically, the log hazard is given by log 
λ (t |A, W) = log                  
 
   , whereas the hazard is  defined as λ (t |A, 
W) =                    
 
     , where       is the baseline hazard.  The 
conditional survival function is then S(t; A,W) =             
 
 
        
     
 
           Typically, the measure of variable importance is the regression 
coefficient   . 
As stated earlier, conventional estimate of   based on partial likelihood is 
biased. Therefore, to generate an estimate of the importance of each biomarker with 
regards to the failure time while taking into account the dependency between 
censoring process and survival and between covariates and exposure, we fitted a 
weighted Cox proportional hazards model .  For this purpose, a 2-stage process was 
implemented: For each subject at each visit, we estimated a weight as a cumulative 
product of a treatment mechanism weight and a censoring weight.  The process of 
weights creation is specified in section 3 below.  These weights were then used in a 
time-dependent Cox proportional hazards model to generate adjusted estimates.  
Under certain assumptions, the inverse probability weighting estimator provides a 
valid test of the null hypothesis of no exposure effect while addressing the issues of 
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confounding and informative censoring (Robins et al, 2000; Robins, 1999; Robins, 
2000).  These assumptions are: 
a. Coarsening at random: We assumed that the covariates used in this 
analysis were sufficient to adjust for both confounding and informative 
censoring.  This implies that within strata of W, A is randomized, and that the 
probability of censoring is independent of the outcome a subject would have 
experienced in the absence of censoring. 
b. Experimental Treatment Assignment (ETA):                that 
is, within all possible levels of the covariates (W), there are both exposed and 
unexposed subjects.   
In addition to the above assumptions, consistency of inverse probability 
weighting estimators relies on correct estimation of the weights models.  In this 
analysis, logistic regression was used to estimate the weights.  However, if there are 
doubts about appropriate functional forms for the biomarker exposure model and 
the censoring model, data-adaptive techniques and cross-validation such as 
Deletion\Substitution \Addition (D\S\A) algorithm (Sinisi and van der Laan , 2004) 
or super learner (van der Laan et al., 2007; Polley and Van der Laan, 2010) could be 
considered.  More detailed discussions on how to select the variables to be included 
in the exposure model can be found in Brookhart et al. (2006). 
Of the three above assumptions, only the ETA is verifiable. For a more 
complete description of these assumptions and their practical applications, the 
interested reader is referred to Cole and Hernán (2008).   
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4.2.2. Measure of Effect and Parameter Estimation 
 
Our goal was to estimate the effect of each biomarker (A) on survival T, while 
using covariate information to adjust for possible confounding, and informative 
drop-out. The parameter of interest was the log hazard ratio from the Weighted Cox 
proportional hazards model associated with each biomarker of interest. 
Suppose A is a binary biomarker with values 1 and 0 denoting the presence of 
absence of a certain biological characteristic.  Using a Cox regression model, we can 
estimate the importance of A with respect to T by taking the difference between the 
two following expressions: 
                                     
 
      
And  
                                     
 
   . 
The difference in log hazards is simply   , the quantity of interest.  It is estimated 
through the method of  partial likelihood (Cox, 1972).  Suppose there were m event 
times, and let the survival times (times to failure) be:  t1 < t2 < ... < tk  with 
corresponding  ―risk sets‖ Rt1, Rt2, ..., Rtk ( The risk set represents the set of subjects 
available for the event at time       Furthermore, let Rj be the list of subjects at risk 
just before tj.  In the standard procedure, parameter estimates are obtained using the 
unweighted ―partial likelihood‖ for  :          
           
                   
 
      
where,  the vector    contains both the biomarker (A) and the covariates (W).  
Taking the log yields: 
 Log             
 
      
 
         
 
              . 
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We then computed the derivative of this function with regards to   and set the 
ensuing score function to 0.  The MLE of            was obtained as a solution to the 
system of the equations: 
     
  
      
 
   
         
 
           
                  
 
    =0         
In the  weighted Cox regression setting, the above Cox partial likelihood score for the 
parameter   should be  modified to incorporate the weight for each subject in the 
risk set at time      Suppose     is the product of the censoring weights and the 
exposure weights for each subject, the above score equation would become: 
     
  
         
 
   
    
 
 
                  
        
 
           
 
     = 0. 
4.2.3. Inverse Probability Weighting Implementation 
 
Two models were used in the estimation of the weights: the biomarker 
exposure model and the censoring model.  While weights from the biomarker 
exposure model allowed one to adjust for confounding, those from the censoring 
model adjusted for possible informative censoring. In the weighted Cox regression 
model, a cumulative product of those two weights for each subject at each time point 
was used.   
4.2.3.1. Biomarker Exposure Model 
 
The first task in creating the weights consisted in estimating the biomarker 
exposure model, P(A|W).  For binary biomarkers, the selection of this model was 
achieved through logistic regression.  Assuming a model of the form 
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     +     , we computed the following expressions of 
probability:               
          
             
 and              
 
             
.     
For continuous biomarkers, a flexible parametric approach, proposed by 
Hirano and Imbens (2004) was implemented to compute a generalized propensity 
score required to create the weights.  First, we postulated a normal distribution of 
the continuous biomarker (A) given the covariates, i.e.              
 
 
     
  .  
Then the parameters   ,   ,  
  were estimated by least squares regression.  
Following Hirano and Imbens (2004), we estimated the generalized propensity 
scores by inserting the estimates of these parameters into the normal density:  
     
 
     
       
              
   
   .  
In the second stage of this approach, we created the weights. Stabilized 
weights for binary biomarkers A were:      
       
          
. For continuous biomarker 
variables, the estimated stabilized weights were constructed as a ratio of densities 
(i.e,       
   
     
) as proposed in Robins et al. (2000);     is the marginal density of 
the continuous biomarker (A), and        is the conditional density of the biomarker 
(A) given the set of covariates (W). To estimate the numerator     we specified a 
normal distribution (i.e.           
   , and then plugged the mean     and the 
empirical variance      of the biomarker (A) values  into the normal density. The 
denominator was estimated based on the generalized propensity score method of 
Hirano and Imbens (2004) described above.  
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4.2.3.2. Censoring mechanism 
 
To correct for informative censoring, a process similar to the one followed for 
binary exposure variables was implemented.   For this purpose, we derived a 
censoring indicator variable that took the value of 1 if the subject was censored and 0 
otherwise.  For each subject i at each time point j, we estimated through a pooled 
logistic regression model the probability of being uncensored conditionally on 
baseline covariates and biomarkers, and the predicted probability from this model 
was used to generate weights for each participants at all time points.  Only non-
administrative censoring was corrected for.  Administrative censorings were treated 
differently in the censoring model than earlier drop-out: while earlier drop-outs were 
assigned a 1 for the censoring indicator at their last visit, subjects administratively 
censored had a 0 if they never had the event and were in the study at least 6 months 
preceding the analysis cutoff date.  The censoring weights, in the presence of non 
time-varying covariates, were defined as: 
   *(t)= 
           
              
 
   , where C(t)=1 if a subject was right censored by time t, 
and 0 otherwise. 
4.2.4. Weighted Cox Proportional Hazards Model 
 
In order to generate final adjusted estimates of the overall effect of each 
biomarker, each subject’s observation was weighted by     x    *(t).  Based on a 
number of applications available in literature, the conventional approach to fitting 
such models  has been to use the time-varying, subject-specific stabilized weights in 
a weighted pooled logistic regression model in order to approximate the parameters 
92 
 
of a time-dependent Cox model.  Relevant examples can be found in Hernán et al. 
(2000), Choi et al. (2002); Cole et al. (2003, 2008), Westreich et al. (2010).  This 
approximation of the Cox regression based on pooled logistic regression works well 
when events are rare, but tends to produce biased estimates of the exposure effect in 
the case of frequent events (Young at al, 2009).  Xiao et al. (2010) argued that an 
alternative approach might be to fit a directly weighted time-dependent Cox 
proportional hazards model and used evidence from simulations to demonstrate that 
this approach always yields unbiased estimates whether or not the outcome under 
study is rare.   
Based on the work of Young at al. (2009) and of Xiao et al. (2010), in this analysis we 
used the counting process style of input to fit a weighted time-dependent Cox 
regression using the PHREG procedure in SAS software ( version 9.2, SAS Institute, 
Cary, NC). We defined an indicator of failure (Dj) at time j within each subject-visit 
[start, stop].  Biomarker exposure served as the lone regressor in the Cox model. We 
accounted for any within-subject correlation induced by the individual weights by 
computing robust estimates of the standard errors based on the sandwich estimator 
(Lin and Wei, 1989).  An additional advantage of this approach is the fact that 
survival estimates were readily available, thus could be used to generate weighted 
survival curves for each biomarker of interest. 
4.3. Application 
4.3.1. Study Population 
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The dataset used for application in this paper came from the Hormonal 
Contraception and HIV Genital Shedding and Disease Progession Study (thereafter 
referred to as GS study), a prospective multicenter study of 306 HIV infected women 
aged 18 to 45 years old from Uganda and Zimbabwe.  This study started in 2001 as 
an add-on to the HC-HIV study (Morrison et al., 2007) and was completed in the 
field in  December 2009.  Women who seroconverted during the course of the HC-
HIV study were recruited for the GS study, based on procedures outlined in 
Morrison et al. (2010). The study specific objectives are described in details 
elsewhere (Morrison et al., 2007, 2010), but one key research question is the effect of 
hormonal contraception on the biological parameters of the infectivity of women 
with primary and chronic HIV infection to their sex partners. 
The GS Study consisted of a baseline visit and follow-up visits at 2, 4, 8 and 12 
weeks following HIV seroconversion, and then every 12 weeks for up to 9 years.  
Women who developed severe HIV infection or who had successive CD4 cell counts 
at or below 200 cells per mm3 were offered highly active antiretroviral therapy 
(HAART) and were seen twice a month initially, then monthly thereafter.  In 
addition to baseline demographic characteristics, at each time point, information on 
various laboratory parameters, reproductive variables, contraceptive exposure, and 
recent sexual behavior was collected.  Laboratory data that was collected included 
HIV plasma viral load, HIV sub-type, CD4, CD8 and total lymphocyte counts, serum 
chemistries, lipid profile,  specimens for the detection of chlamydial, gonococcal, 
syphilis, herpes simplex virus 2 (HSV-2), and Human papillomavirus (HPV) 
infections.  The study also collected information on hormonal contraceptive use, 
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diisease progression parameters, as well as virologic, immunologic, and clinical 
response to HAART among hormonal and non-hormonal contraceptive method 
users. For a detailed description of the study population and procedures, the reader 
is directed to Morrison et al. (2010).        
4.3.2. Outcome Definition and Censoring 
 
In this analysis, the time variable was defined as the time from estimated HIV 
infection date to either the second of two successive CD4 cell counts below 350 
cells/mm3 or the second CD4 cell count of 350 cells/mm3  or below within a six 
month period.    In both cases, we considered two CD4 counts below 350 cells/mm3 
instead of a single count below 350 cells/mm3 because CD4 cell count measurements 
tend to be highly variable both from person to person and within an individual 
patient.  Taking more than one measurement helps mitigate the effect of large 
individual variability in CD4 cell counts values.   
The choice of the threshold of 350 cells/ mm3 for CD4 cell counts was based 
on current guidelines for the use of antiretroviral agents in adults and adolescents 
infected with HIV-1 in the absence of an AIDS-defining illness (Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2008; Hammer et al., 2008). 
Also, evidence from the literature suggests that early initiation of antiretroviral 
therapy before the CD4 cell count falls below 350 cells per mm3 significantly 
improves survival, as compared to deferred therapy (Sax and Baden, 2009; Kitahata 
et al., 2009; When to Start Consortium, 2009).  
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In this study, censoring occurred either by death, loss to follow-up, or by end 
of study observation.  In this analysis, any subject who was still alive, did not 
experience the outcome and was still in the study at the end of 2009 was censored at 
their last recorded visit.  This kind of censoring, referred to as administrative 
censoring, was treated differently in the censoring mechanism model, than drop outs 
that occurred 1 year or more prior to the data cutoff for this analysis.  As mentioned 
in section 2, drop-outs as a result of death or loss to follow-up (depending on the 
type of loss to follow-up) could be non-random.  Thus, the need to control for both 
confounding and informative censoring motivates the application of inverse 
probability of treatment and censoring weighting to this data set. 
4.3.3. Biomarker Exposure Variables and Covariates   
                                                                                      
In the analysis, we controlled for a host of risk factors reported in the 
literature to be predictive of incident HIV infection or clinically associated with HIV 
disease progression (Van Der Pol et al., 2008).  These covariates include age, 
country, primary partner risk, STI history, having more than one sex partner, 
number of coital acts in previous 3 months, frequency of nights away from home by 
study subject’s partner, condom use consistency, study subject’s partner’s sexual 
behavior and risk, and breastfeeding. 
The biomarkers for which we estimated a measure of variable importance 
included plasma viral load, HIV sub-type (A, C, D), hemoglobin level, CD4 cell 
counts at baseline, CD8cell counts, total lymphocyte counts, HSV-2 status, CD4/CD8 
ratio, and CD4 percentage.  
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Finally, baseline in this analysis was defined as the latest available biomarker 
and covariate measurements at 6 months after the estimated HIV infection date.  A 
number of participants, however, were missing baseline data related to a few 
biomarkers.  For these subjects, baseline was redefined as the first GS visit with 
available biomarker data.  
4.4. Data Analysis 
 
Because the censoring process was time-dependent, we used the counting 
process formulation to create the dataset required for the analysis. Following the 
work of Anderson and Gill (1982) who developed the notion of the counting process 
style of input, we allowed each individual in the sample to have multiple records, one 
per measurement occasion, containing a time interval (start, stop), a censoring 
indicator showing the status of the interval, and  a vector of explanatory variables, 
including the biomarker of interest.  This analysis was restricted to biomarkers and 
covariates selected 6 months after estimated date of infection. They remained fixed 
at all follow-up visits.  No time-varying exposure or covariates were involved. 
In the raw data, the continuous biomarker variables were measured on vastly 
different scales.  The fact that the regression coefficients in the weighted Cox 
proportional hazards model depended on the units of measure made it difficult to do 
meaningful comparison based on metric regression coefficients alone.  To 
circumvent this problem, we incorporated standardized continuous biomarker 
variables (created by subtracting the mean and dividing by the standard deviation) 
rather than the raw continuous variables in the different regression models.  
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Essentially, a Z-score was computed for each continuous variable: CD4 cell counts at 
baseline, CD8 cell counts, HIV RNA, Hemoglobin level, CD4/CD8 ratio, CD4 
percent, and lymphocyte counts.  The standardization resulted in a mean of 0 and a 
variance of 1 for each standardized variable, making the regression coefficients for 
the affected variables directly comparable to one another.  No change was made to 
the binary biomarker variables. The standardized coefficients should then be 
interpreted in terms of change in the clinical response variable resulting from a 
change of one standard deviation in the continuous biomarker variable of interest.  
The p-value for the test of the hypothesis of no exposure effect stays the same 
whether or not one uses raw or standardized variables. 
4.4.1. Weights Estimation 
 
To estimate the weights, we fitted four different pooled logistic regression 
models.  From the first two models, we generated the predicted probabilities 
required to compute the stabilized weights associated with the biomarker exposure.  
The numerator of the weights was obtained from an-intercept only regression model 
with biomarker (A) as the dependent variable, while estimates for the denominator 
came from a multivariate regression model with  the same covariates listed above 
plus  a smooth function of study duration represented by natural cubic splines with 4 
knots at the 5th, 35th, 65th, and 95th percentiles (Harrel, 2001).  The use of the cubic 
splines in lieu of a linear term relaxed the dependency on the strong linearity 
assumption with regards to duration of follow-up while allowing for time-varying 
hazards. 
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Two additional pooled logistic models were used for estimating the censoring 
weights.  All the covariates listed above, including the cubic splines, were used in the 
estimation of the numerator.  For the denominator, the biomarker exposure variable 
of interest was included as an additional regressor. 
For each subject i at each time point j, we subsequently computed an overall 
weight that was the product of stabilized weights obtained from the biomarker 
exposure model and the censoring mechanism.  These weights were then entered 
into the Cox model to generate the adjusted estimates of the variable importance 
measure for each biomarker.  This process was followed separately for each 
biomarker               There were then k estimates of    
    of variable 
importance measures and k p-values denoted as P1, P2,…, Pk.  We adjusted the p-
values for multiplicity testing to control the false discovery rate.  The Benjamini and 
Yekutieli (2001) False Discovery Rate (FDR) controlling procedure was used to 
account for the dependence of the test statistics.  Significance for each biomarker 
was assessed by comparing related adjusted p-value to the 0.05 alpha level.  A lower 
p-value denoted a better measure of importance. 
4.4.2. Results 
 
In the GS study, the median age at enrollment was 27 years.  Women from 
Zimbabwe accounted for 58.5% of the population while those from Uganda made up 
the remaining 41.5%.  About 8% of all study subjects had at least two sex partners 
while 14% had a STI history, 8% were breastfeeding, and 45% displayed STI 
symptoms.  These women averaged 11.2 (Standard Deviation [SD] = 15.5) sex acts 
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per month, but only 35% of them reported consistent condom use.  On average, the 
partners of these women spent 10 (SD=15.2) nights away from home, and 75% of 
those partners had been reported to have had sex with another woman in the three 
months prior to enrollment in the study. Finally, 59% of the subjects’ partners met 
the study definition for primary partner risk, a composite variable that included 
having a partner with HIV, urethral discharge, weight loss, nights spent away from 
home, or a history of sex with female sex workers. 
Table 7 presents the distribution of the stabilized weights.  Overall, the mean 
for the weights computed for each biomarker was clustered around 1, which is a 
desired result.  All biomarkers displayed small variability in the weights.   
For each biomarker, we derived estimates of 5-year cumulative probability of 
survival with corresponding 2-sided 95% confidence intervals, using the Kaplan 
Meier estimator (Kaplan and Meier, 1958).  In this context, survival was defined as 
the probability of not experiencing the event of interest in the first 5 years since 
estimated infection date.  For the purpose of survival curves estimation, all 
biomarkers measured on a continuous scale were dichotomized based on meaningful 
clinical values suggested in literature (Table 8).   In short, having the following 
biomarker characteristics was associated with a 5-year cumulative probability of 
survival  40%: CD4 at baseline   500 cells/mm3 (35% survival rate), Lymphocyte 
count < 1200 cells/mm3 (35%), and CD4 Percentage    20 % (30%).   
We computed both weighted and un-weighted estimates of the importance of 
each of the 11 biomarkers under consideration (Tables 9 and 10).  The un-weighted 
estimates were obtained from a standard Cox proportional hazards model with the 
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following covariates: age, country, primary partner risk, STI history, having more 
than one sex partner, number of coital acts in previous 3 months, frequency of nights 
away from home by study subject’s partner, condom use consistency, study subject’s 
partner’s sexual behavior and risk, and breastfeeding. The results in Table 9 suggest 
that, when the standard Cox model was used, the following biomarker variables had 
a significant impact on CD4 cell counts: Baseline CD4 Cell count, CD4/CD8 T-cell 
Ratio, Plasma Viral Load, and Lymphocyte Count.   
In the weighted analysis (Table 10), the same four biomarkers were found to 
exert a significant impact on the time to the second successive drop of CD4 cell 
counts below the threshold of 350 cells/mm3.  Based on the magnitude of the p-
values, the most important biomarkers were baseline CD4 Cell count, CD4 
Percentage, CD4/CD8 Ratio, Lymphocyte Count and HIV Subtype A.  Note that, in 
the pseudo-population created by the weights, HIV subtype A only reached 
borderline statistical significance.   
Evidence from both tables 10 and 11 suggests that a lower hazard (better survival) 
was associated with increases in Baseline CD4 Cell count, CD4 Percentage, CD4/CD8 
Ratio, Lymphocyte Count, hemoglobin levels, and with being of HIV Subtype A.  For 
these biomarkers, the log hazard ratio is negative.  Conversely, a higher hazard 
(lower survival) was linked to increases in Plasma Viral Load (Log10/mL), in CD8 
cell counts, and with being of HSV-2 positive or of HIV subtype C or D (positive log 
hazards ratio).   
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4.5. Discussion  
 
In this study, we applied a flexible tool for estimating biomarker exposure 
effects in observational data, taking into account covariates information.  The list of 
biomarkers deemed significant as well as the direction of the associations noted - as 
suggested by the sign of the log hazards ratio or by a visual inspection of the adjusted 
survival curves (not shown) - is consistent with current clinical and medical 
knowledge of HIV infection.  For instance, a negative log hazards ratio was expected 
- and found - for increases in lymphocytes counts.  It is known that total lymphocytes 
counts (TLC) tend to decrease as a result of HIV infection and disease progression.  
Also, the significant association found with the outcome is consistent with research 
findings of a relatively high positive correlation between absolute values of TLC and 
CD4 cell counts or between changes in TLC and CD4 cell counts (Badri and Wood, 
2003; Mwamburi  et al., 2005).  This finding could have practical applications for 
HIV medical care. As a measure of a patient’s immune capacity, CD4 cell count is 
considered as a standard method for determining eligibility for highly active 
antiretroviral therapy (HART) and HIV disease progression.  However, its 
measurements require highly skilled personnel and costly maintenance of 
sophisticated equipment, and these costs could be prohibitive in resource-deprived 
countries. Cheaper alternatives identified in this study (e.g. TLC), upon further 
evaluation, could potentially support decision-making with regards to the initiation 
of antiretroviral therapy or could help monitor patients’ immune status during 
therapy in the absence of expensive CD4 measurements.  Overall, the application of 
the weighted Cox proportional hazards model to the GS study data provides valuable 
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information for HIV medical care, and should be considered in the panoply of 
techniques used in biomarker assessment. 
In addition to its ability to produce a consistent estimate of the effect of a 
given exposure, the Weighted Cox proportional hazards model is appealing because 
it makes it easier to create adjusted survival curves, which can be viewed as a graphic 
summary of the data averaged over the covariates used in the weights models.  While 
adjusted estimates from the Cox proportional hazards model have been ubiquitously 
used in the reporting of results from survival analysis, survival curves have been 
used less frequently in observational studies (Hernán, 2010) due to the lack of a 
standard method for dealing with confounding.   There have been attempts in the 
literature to generate adjusted survival curves from the conventional Cox model, but 
these applications were fraught with problems (Nieto and Coresh, 1996).  One 
notable shortcoming identified in Nieto and Coresh’s paper was the inability to 
adjust for continuous covariates.  In their 2004 paper, Cole and Hernán proposed 
and demonstrated the idea of using survival estimates from the weighted Cox model 
to generate adjusted survival curves.  This method was simple, easily implemented 
using standard statistical software, did not involve stratification on any covariate, 
and accommodated both continuous and time-varying covariates.  Thus, even when 
results and conclusions from standard covariate adjustment through the 
conventional Cox proportional hazards model are identical to those from a Weighted 
Cox proportional hazards model performed on the same data, the latter method has 
the advantage of readily generating adjusted survival curves.  Certainly, the use of 
survival curves to report results from time to events analyses is encouraged (Hernán, 
103 
 
2010) because survival curves have served as effective tools for displaying 
informative and meaningful summary of study findings over the span of the entire 
study period.     
This study has limitations.  We applied the weighted Cox proportional hazards 
model under the assumption of no unmeasured confounders for biomarker exposure 
and censoring.  There is no direct way to verify whether there remained any putative 
confounders that were not part of the vector of covariates (W) used in this study. All 
measured confounders are controlled for in the weights, and bias could still exist if 
some important confounding variables were not measured and, therefore, were not 
included in the weighted models.  To guard against violation of this assumption, we 
included process a number of covariates believed to be related to the exposure of 
interest and the outcome (based on existing literature and expert knowledge) in the 
modeling process (Van Der Pol, 2008).  Another potential limitation could be the 
occurrence of practical violations of ETA.  Research by Wang et al (2006), 
Neugebauer and van der Laan (2005), and by Moore et al (2010) has demonstrated 
how ETA violations could result in significant bias in the inverse probability 
weighted estimator of causal effect models.  In real life applications, it is not 
uncommon for an exposure to occur with a small probability or even with 0 
probability within a given stratum of subjects.  Also there may just be practical 
violations of ETA, defined as the occurrence of random 0 or 1 probability by chance.  
In this study, we have used a number of biomarkers measured on continuous scales, 
and it is known that ETA violation tends to be frequently associated with the use of 
continuous exposure variables.  To reduce the impact of practical violations of ETA 
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on the stability of our estimator and to ensure an adequate bias-variance trade-off, 
we set all estimated probabilities from both the censoring and exposure models 
below 0.01 to 0.01, as suggested in Bembom et al. (2008).  Another technique 
implemented in this analysis to mitigate the effects of possible ETA violations was 
the use of stabilized weights, which allowed for a weaker form of the ETA 
assumption (Wang et al, 2006). 
4.6. Conclusion 
 
This paper has provided an overview of the inverse probability weighting 
estimator and its application to the problem of biomarker selection in a survival 
setting.  We used an example of observational HIV infection data to illustrate the 
appropriateness of this method as a tool for generating marginal variable importance 
measures for each biomarker of interest.  This example, however, involved only static 
exposures and covariates.  In actuality, biomarker data may involve time-varying 
covariates that could be both a risk factor for the outcome and a predictor of 
subsequent exposure.  Furthermore, in those data, past exposure history might 
predict the risk factor.  In such occurrences, the methods used in this paper should 
be extended to account for time-dependent covariates and exposure.  One suitable 
solution could be the use of Robin’s marginal structural models (Robins et al, 2000; 
Hernan et al, 2000), which have gained widespread use and acceptance in dealing 
with time-varying confounders.  Another possible alternative could be the 
collaborative targeted maximum likelihood estimation (van der Laan and Gruber, 
2009; Stitelman and Van der Laan, 2010), a methodology developed by Van der 
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Laan specifically with observational data in mind.  This extension of the theory of 
targeted maximum likelihood (Van der Laan and Rubin, 2006) estimation is 
believed to provide substantial gains in both robustness and efficiency over 
commonly used methods.
  
 
 
CHAPTER 5: CONCLUSION 
 
5.1. Overview of the study 
 
The objective of this research was to evaluate the use of biomarker data for 
disease detection, diagnosis, and prognosis.   Because of recent development of new 
biological and molecular techniques, a large number of new biomarkers have become 
available. Determining the predictive and diagnostic value of these biomarkers, 
singly or in combination, is essential to their being used effectively.  This has spurred 
the development of new statistical methodologies that can exploit this wealth of 
information to adequately explain the relationship between biomarkers and 
outcomes of interest.  This research used novel statistical methods to identify 
biomarkers with good performance characteristics while providing guidelines for 
biomarker data collection and assessment, such as sample size requirements.   
The central question addressed in this dissertation was the following: Given a 
large set of biomarkers that potentially predict a clinical outcome, how can one make 
a determination as to which ones are the most important?  To answer this question, 
we applied different estimation methods to generate a marginal variable importance 
measure (VIM) separately for each biomarker.  Then we used the estimated VIM to 
make inferences about the importance of each biomarker.  We performed biomarker 
evaluation in three different settings: Point treatment, longitudinal repeated 
measures, and time to event.  Methods applied at each setting were as follows: 
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5.1.1. Point Treatment  
 
Because CD4 cell count, as an indicator of disease progression, is frequently used 
to determine eligibility for HAART initiation, it is of interest to know as early as 
possible which subjects from a cohort are most at risk for CD4 cell count depletion.  
This information could then guide monitoring efforts or HAART initiation policies.  
The evaluation of biomarker selection methods that could provide such information 
in the short term is the crux of chapter 2.  In this analysis, the outcome was a binary 
variable representing 2 successive drops in CD4 count to below 350 cells per mm3 in 
the first two years following the viral set point (121 days from estimated infection 
date).   Methods discussed in this context included Targeted maximum likelihood 
estimation (TMLE), flexible propensity score weighting (PSW), and incremental 
value estimation based on partial area under the Receiver-Operating Characteristic 
(ROC) curve.  TMLE and PSW were both applied in a counterfactual framework and 
involved maximizing the following objective functions: =   [E(Y=1|   =1, W) - 
E(Y=1|   =0, W)] (for binary A), and  =   [E(Y=1|   =a, W) - E(Y=1|   = , W)] 
(for continuous A).  Both methods involved two nuisance parameters P(Y|A,W) and 
P(A|W).  In the estimation of  the variable importance measure, the TMLE  added a 
covariate created from P(A|W) to the initial regression model, while the PSW 
method used weights from estimated propensity scores to incorporate the 
relationship between A and W in the regression P(Y|A,W).    
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In the third method highlighted in chapter 2, called incremental value 
estimation for partial area under the ROC curve, we defined variable importance 
measure as the improvement in classification performance gained by adding each 
biomarker separately to the set of covariates.  More specifically, we generated an 
ROC curve for a combination of biomarker and covariates using the model  
P(Y=1|A,W) and  another ROC curve for the covariates alone based on P(Y=1|W).  
The VIM for each biomarker was given by the difference in pAUC between the two 
models.   
5.1.2. Longitudinal Repeated Measures 
 
In this analysis, we extended the TMLE methodology to longitudinal repeated 
measures to look at trends over a longer term.  We addressed the gap caused by the 
absence of a generally accepted approach for generating a scalar value representing a 
measure of variable importance over time.  We proposed and implemented a 
methodology integrating both TMLE and the computation of the area under/above 
the LOESS curve.  Computation of the index measure of interest is based on the 
composite Simpson’s rule for numerical integration and is given by: 
           
 
 
 
 
 
              
  
 
         
  
 
         
 
   
   
     where the 
time interval [a, b] is subdivided into 2m subintervals                  
   of equal 
width    
   
  
 , and f(.) are the predicted values from the LOESS model relating  the 
VIM, , to time.  We then compared results from this approach to those obtained 
from an autoregressive model. 
109 
 
5.1.3. Time to Events 
 
In this analysis, we took right censoring into consideration.  The outcome was 
defined as the time from estimated HIV infection date to either the second of two 
successive CD4 cell counts below 350 cells/mm3 or the second CD4 cell count of 350 
cells/mm3  or below within a six month period.  Control for measured confounding 
and potential informative censoring was achieved through the use of stabilized 
weights in a time-dependent Cox proportional hazards model.  From the log hazard 
given by log λ (t |A, W) = log                  
 
   , the parameter     estimated 
through partial likelihood, captures the effect of the biomarker and represents the 
VIM of interest. 
5.1.4. General methodology  
 
Under each method, we carried out a separate analysis to estimate a marginal 
measure of importance of each biomarker, controlling for measured confounding 
variables. This measure of importance represents the effect of each biomarker on the 
outcome.  For inference, we applied a nonparametric bootstrap.  We determined the 
importance of each target biomarker based on the magnitude of the p-value from the 
hypothesis test of a non-zer0 mean bootstrapped estimate for each biomarker.  To 
take into account multiple testing and dependency of the different test statistics, we 
applied the Benjamini and Yekutieli procedure for controlling the False Discovery 
Rate (FDR).  Statistical significance was reached if the FDR-adjusted p-value was 
smaller than or equal to alpha=0.05, with smaller p-values indicative of greater 
importance.  A dataset from the Hormonal Contraception and HIV Genital Shedding 
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and Disease Progression Study (GS Study) that included longitudinal HIV infection 
data on a sample of 306 HIV-infected adult women from Uganda and Zimbabwe was 
used to develop and evaluate the methods discussed in this dissertation. 
5.2.  Summary of the Results and Discussions 
 
In the cross-sectional analysis, the most important biomarkers under the 
TMLE methodology, among the 11 biomarkers considered, were baseline CD4 cell 
count and CD4/CD8 T cell ratio.  Under the PSW approach, the biomarkers selected 
as most important were: HSV-2 status, CD4/CD8 T cell ratio, baseline CD4 cell 
count, and plasma viral load.  No biomarker was selected as important by the 
incremental value method. 
We made further statistical evaluation of these methods by performing 
simulations to assess their finite sample properties.  Our results suggest that the 
PSW tend to perform better than the other methods in small to moderate sample 
sizes (i.e.  0 <N   200).  The TMLE performed reasonably well in moderate to large 
sample sizes (i.e. N   100).  Finally, the incremental value approach displayed an 
unsatisfactory ability in detecting significant biomarkers when the sample size is less 
than 200, but worked well with sample sizes over 200. 
In the longitudinal repeated measures analysis, the two methods under 
consideration yielded the same conclusion: Among the 11 biomarkers, the most 
important ones, based on the magnitude of the p-values, were baseline CD4 cell 
counts, HIV subtype, and HSV-2 status.  Simulation studies assessing sample size 
issues indicate that performance of both methods again depends on sample size. 
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In the time to events analysis, the most important biomarkers were baseline CD4 
Cell count, CD4 percentage, CD4/CD8 ratio, lymphocyte count and HIV subtype. 
The above results appear to indicate that the list of biomarkers selected as 
important depends on the type of analysis performed.  It would be tempting to 
expect the list of biomarkers deemed important to be consistent across all three 
analyses (point treatment, longitudinal repeated measures, and time to events).  It 
should be noted however, that the three major kinds of analyses conducted on the GS 
data did not address the same research question, as the definition of the outcome in 
each analysis incorporated different durations of time.    In the point treatment 
analysis, for instance, only the first two years following viral set point was of interest.   
This analysis inherently used less information from the GS data than the time to 
event analysis or the longitudinal repeated measures analysis, and the 2-year time 
period may not have been sufficient to detect the effect of certain biomarkers.  
Another possible explanation for the lack of consistency in the results could be the 
behavior of the biomarkers over time.   
Insights gained from the LOESS curves in chapter 3 suggest that the longevity of the 
predictive effect of certain biomarkers may increase, decrease, or stay relatively 
constant over time.  Thus, it is quite possible that some biomarkers could have an 
effect only in the short term, while the impact of other biomarkers may have been 
more pronounced in the longer term. 
If we were to consider results from the longitudinal repeated measures as the 
gold standard in this dissertation, on the basis of the amount of information 
available in the data, we would conclude that the most important biomarkers that 
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predict CD4 cell counts are:  Baseline CD4 cell counts, HIV subtype, and HSV-2 
status.  Of those three biomarkers, two (baseline CD4 cell count, HIV subtype) were 
selected as important in the time to events analysis, the second method in terms of 
amount of information used. In all three analyses, baseline CD4 cell count appeared 
on the list of the most important biomarkers.  This is consistent with results from 
other studies that found a similarly strong association the baseline CD4 count and 
the subsequent CD4 response for patients on HAART therapy (Byakwaga et al., 
2009; Florence et al., 2003; Le Moing et al., 2007; Robbins et al., 2009). 
While none of the results of the three types of analysis done on the GS data 
seem to contradict current medical knowledge, we should approach them with 
caution.  The definition of all 3 types of outcomes in this research involved time since 
infection.  In the GS Study, investigators knew the last time point where a participant 
was HIV-uninfected, so they have been able to combine this information with the 
date of the first visit where that person was confirmed infected to generate their best 
estimate of infection date.  In standard public health settings, this information is 
generally not available; thus, one may not know at what point in time relative to the 
infection date the  biomarkers have been measured.  An additional cautionary note 
concerns the use of HIV subtype results from this research.  The HIV subtypes A, C, 
and D are prevalent in African but not in Europe or North America.  Therefore, the 
results reported here may not be applicable to Western developed countries where 
subtype B is largely dominant. 
5.3. Contributions of the Study 
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From a public health perspective, this research is relevant for several reasons. 
It enabled us to identify from the GS study potentially useful candidate biomarkers 
based on their importance with regards to the outcome of low CD4 cell count.  For 
instance, analyses of the GS data in cross-sectional, longitudinal repeated measures, 
and survival contexts each identified baseline CD4 cell counts as one of the most 
important biomarkers. Based on this finding, a potential action item in public health 
practice could be the identification of patients at risk for CD4 depletion so that they 
could be monitored more closely and started on HAART, when necessary.  To 
accomplish this, it might be necessary to obtain an initial CD4 measure when 
infection is discovered, followed by repeated CD4 but perhaps less frequently for 
those with a high initial CD4 (say > 500 cells/mm3).  Tools such as the LOESS curve 
used in this research could be used to determine exactly when additional 
measurements are needed.  This could potentially help save lives, time, and money, 
especially in resources-deprived countries where the costs to measure CD4 are often 
prohibitive. 
From a more global standpoint, research of this kind has the potential to 
contribute to the advancement of both clinical and public health practice.  
Application of analytic methods used in this research to generate a list of useful 
candidate biomarkers based on their true importance in predicting a given outcome, 
could potentially help reduce waste and time by directing biologists’ focus on the 
best biomarkers, and by allowing practitioners to direct resources towards the most 
promising candidate biomarkers.  From a statistical standpoint, such a list can 
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further direct research on establishing the level of surrogacy of the significant set of 
candidate biomarkers. 
5.4. Strengths of the study  
 
This research draws its strength from the significance of the subject matter 
and the comprehensiveness of the implemented research plan. 
5.4.1. Significance and timeliness of the subject matter 
 
Biomarker identification has recently been the focus of tremendous research 
activity, from basic laboratory research to clinical and epidemiological 
investigations.  The work accomplished in this dissertation contributes to the 
statistical literature by addressing the issue of biomarker selection in various 
contexts (cross-sectional, longitudinal, survival) and by proposing a novel procedure 
based on non parametric regression (LOESS) to compute a longitudinal variable 
importance measure for biomarker evaluation.  This research provides also valuable 
information for HIV medical care.   
As biomedical research is increasingly moving towards a new era of predictive, 
preventive, and personalized medicine, successful biomarker selection and 
validation through a combination of enhanced genomic research techniques and 
novel robust statistical methods could speed early detection, diagnosis, and 
treatment of disease.  For instance, if biomarker identification is improved, this 
could accelerate introduction of treatment early in the disease process potentially 
leading to reduction in disease severity, complications and mortality. The end result 
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will be a reduction in the burden of disease and enhancement in life expectancy.  
Thus, patients and the public at large stand to benefit from any new reliable 
statistical method for biomarker selection that contributes to an early disease 
diagnosis or to a rapid, efficient, and economical drug development process.  Even 
though an HIV infection dataset is used in this research, the methods implemented 
in this study can be applied to other areas of biomedical research and public health 
practice, including vaccine studies. 
5.4.2. Comprehensiveness of the plan 
 
This research encompasses the assessment of innovative new statistical 
methodologies for biomarker identification that incorporate covariate information.  
The use of these methods for not only cross-sectional data, but also in the 
longitudinal and time-to event settings, combined with their application to a unique 
and rich data set of HIV infection data, and the simulation studies to develop sample 
size guidelines, create a comprehensive plan.    
5.5. Limitations of the Study 
 
This study has limitations.  The methods implemented in this research 
(TMLE, PSW, Weighted Cox regression) rely on the assumption of no unmeasured 
confounders, i.e. that within strata of covariates (W), the target biomarker (A) is 
randomized.  In this analysis, we tried to identify all important covariates (W) 
believed to be related to both potential outcomes and exposure (A) based on the 
literature or expert knowledge, and include them in the estimation of the effect of 
each biomarker.  There is, however, no direct way to verify whether there remained 
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any putative confounders that were not part of the vector of covariates (W) used in 
this study.  
Another potential limitation could be the occurrence of practical violations of 
experimental treatment assignment (ETA) in the three methods that used 
information from the biomarker exposure assignment P(A|W).   In real life 
applications, it is not uncommon for an exposure to occur with a small probability or 
even with zero probabilities within a given stratum of subjects.  In this study, we 
have used a number of biomarkers measured on continuous scales, and it is known 
that ETA violation tends to frequently be associated with the use of continuous 
exposure variables.  Such violations could result in biased exposure effects.  In the 
propensity score-based methods, we aimed at reducing the impact of practical 
violations of ETA on the stability of our estimators by either truncation of estimated 
probabilities from the censoring and exposure models or by use of stabilized weights.   
Sample size is another limitation of this study, especially in the cross-sectional 
analysis.  Over half of the biomarkers under consideration in this analysis had 200 or 
fewer non-missing observations because women not seen for more than 6 months 
following estimated infection date have missing data for biomarker measures.  In the 
marginal analyses that we performed for each biomarker one at a time, all records 
with missing biomarker information were excluded from the models.  As shown in 
simulation assessing the finite sample properties of the methods outlined in chapter 
2 (TMLE, PSW, and incremental value estimation), sample size does affect the ability 
of all these methods to detect ―true‖ significant biomarkers; all three showed a 
decreased ability in pinpointing significant biomarkers at smaller sample sizes (e.g. 
117 
 
N=100).  Hence, sample size constraints may have hindered us from detecting 
additional significant biomarkers in the GS dataset.  The sample size cut-points we 
identified through our simulations in chapter 2 and chapter 3 should serve only as 
starting point towards establishing sample size requirement guidelines for future 
data collection and assessment in biomarker studies where these selection methods 
are used. 
Finally, in this research, both biomarkers and covariates were chosen at 6 
months from estimated infection date.   The inclusion of time-varying biomarkers 
and covariates in both the longitudinal repeated measures analysis and in the time to 
events analysis might be a more suitable strategy for capturing the various 
dimensions of the clinical outcome, as compared to single fixed measurements.  It is 
possible that some biomarkers would exhibit a significant effect on CD4 cell count 
only when they are allowed to vary over time along with covariates of interest.  In 
such situations, measures taken at baseline might not have been good enough 
predictors of the outcome over the long term. 
5.6. Recommendations for future Research 
 
In this research, both biomarkers and covariates were chosen at 6 months 
from estimated infection date and remained fixed.  One future area of research could 
be the inclusion of time-varying biomarkers and covariates. Biomarker data often 
include time-varying covariates that could be both risk factors for the outcome and 
predictors of subsequent exposure.  Furthermore, past exposure history might 
predict those risk factors.  One suitable framework for dealing appropriately with 
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time-dependent covariates and exposure could be Robin’s marginal structural 
models (Robins et al, 2000; Hernan et al, 2000).  Another possible alternative could 
be the collaborative targeted maximum likelihood estimation (van der Laan and 
Gruber, 2009; Stitelman and Van der Laan, 2010), a methodology developed by Van 
der Laan specifically with observational data in mind.  This extension of the theory of 
targeted maximum likelihood (Van der Laan and Rubin, 2006) estimation is 
believed to provide substantial gains in both robustness and efficiency over 
commonly used methods. 
 Another logical and intuitive step from this research could be the evaluation 
of the role of a multi-marker strategy in improving diagnostic accuracy and 
prediction.  Specifically, it would be of clinical significance to determine whether the 
use of a 2 or 3-marker combination (e.g. baseline cd4, HIV subtype, and HSV-2 
status) would be superior to a single marker (e.g. baseline CD4 cell count) in terms of 
risk prediction.  To this end, one can utilize expert knowledge to make appropriate 
combinations of all biomarkers selected as important in this research.  Once the 
biological plausibility of these marker combinations has been established, one can 
then embark on a rigorous statistical evaluation aimed at selecting the optimal 
biomarker combination.  Of course, a drawback is that several biomarkers would 
have to be measured, perhaps even more than once, thus possibly making this 
approach less feasible in resource-constrained settings. 
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TABLES AND FIGURES 
 
Table 1: Estimates of Variable Importance Measures for Each Biomarker and Associated p-values 
 TMLE 
Weighted Logistic 
Regression 
Partial ROC (0.05) 
Biomarker VIM 
Unadjusted 
p-value 
p-
value
 a
  
VIM 
Unadjusted  
p-value 
p-
value
 a
 
 
Incremental 
partial 
AUC
b
 
Unadjusted 
p-value 
p-
value
 a
 
 
CD4 at 
baseline  
0.2064 0.0004 0.0070 0.2316 0.0007 0.0079 0.0082 0.3100 1.0000 
Plasma 
Viral Load 
0.0519 0.2784 1.0000 0.1537 0.0024 0.0200 0.0029 0.2400 1.0000 
CD8 Count  0.0535 0.2705 1.0000 0.1410 0.0920 0.5092 0.0013 0.7300 1.0000 
CD4/CD8 T 
cell Ratio  
0.1071 0.0003 0.0070 0.1113 0.0004 0.0059 0.0002 0.9100 1.0000 
Lymphocyte 
count  
0.1044 0.1714 1.0000 0.1843 0.2298 0.8720 0.0006 0.6100 1.0000 
CD4 
percent  
0.2779 0.0103 0.1138 0.3663 0.0514 0.3414 0.0091 0.2700 1.0000 
HIV 
subtype A 
0.1908 0.5362 1.0000 0.2318 0.3434 1.0000 0.0000 1.0000 1.0000 
HIV 
subtype C 
-
.06687 
0.8731 1.0000 0.1827 0.1809 0.8586 0.0000 0.8400 1.0000 
HIV 
subtype D 
0.2200 0.4789 1.0000 0.1295 0.4519 1.0000 0.0001 1.0000 1.0000 
Hemoglobin 0.0471 0.4225 1.0000 0.1261 0.2363 0.8720 0.0001 0.9700 1.0000 
HSV-2 
status 
0.0078 0.8667 1.0000 0.1088 <.0001 <.0001 0.0000 1.0000 1.0000 
Note: Results based on 5000 bootstrap samples. 
a Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR) procedure. 
b At a false positive rate of 0.05. 
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Table 2: Results from 5000 bootstrap samples for five simulated biomarkers                                                                                                                 
based on Targeted maximum Likelihood Estimation for Variable importance Measure 
 N=150 N=200 N=250 
Biomarker VIM 
Unadjusted 
 p-value 
p-
value* 
 VIM 
Unadjusted 
 p-value 
p-
value* 
 VIM 
Unadjusted  
p-value 
p-
value* 
 
A1 0.087 0.7040 1.0000 0.028 0.8923 1.0000 0.021 0.9103 1.0000 
A2 0.339 <.0001 <.0001 0.314 <.0001 <.0001 0.321 <0.0001 <.0001 
A3 0.218 0.0239 0.1367 0.211 0.0113 0.0643 0.218 0.0029 0.0166 
A4 -
0.036 
0.6873 1.0000 -0.057 0.3855 1.0000 -
0.056 
0.3379 1.0000 
A5 -
0.043 
0.4745 1.0000 -0.034 0.4958 1.0000 -
0.034 
0.4713 1.0000 
* Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR). 
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Table 3: Results from 5000 bootstrap samples for five simulated biomarkers                                                                                                                
based on Propensity Score Weighting for Variable importance Measure 
 N=150 N=200 N=250 
Biomarker VIM 
Unadjusted  
p-value 
p-
value* 
 VIM 
Unadjusted 
 p-value 
p-
value* 
 VIM 
Unadjusted  
p-value 
p-
value* 
 
A1 0.111 0.2173 0.6203 0.111 0.0666 0.2536 0.084 0.1693 0.4832 
A2 0.310 <.0001 <.0001 0.284 <.0001 <.0001 0.301 <.0001 <.0001 
A3 0.189 0.0088 0.0505 0.193 0.0001 0.0006 0.204 <.0001 <.0001 
A4 -0.044 0.6438 1.0000 -0.070 0.1533 0.4374 -0.056 0.0298 0.1134 
A5 -0.059 0.2027 0.6203 -0.042 0.2543 0.5806 -0.036 0.3678 0.8398 
* Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR). 
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Table 4: Results from 5000 bootstrap samples for five simulated biomarkers                                                                                                                
based on Incremental Value estimation for partial area under the curve 
 N=150 N=200 N=250 
Biomarker 
ΔpAUC 
(0.05) 
 
Unadjusted  
p-value 
p-
value* 
 
ΔpAUC 
(0.05) 
 
Unadjusted 
p-value 
p-
value* 
 
ΔpAUC 
(0.05) 
 
Unadjusted 
p-value 
p-
value* 
 
A1 .001 0.0660 0.3768 .001 0.0600 0.3425 .001 .1600 0.6089 
A2 .006 0.1400 0.5328 .004 0.1300 0.4947 .010 .0016 0.0091 
A3 .005 0.0200 0.2283 .005 0.0007 0.0081 .007 <.0001 <.0001 
A4 -.001 0.3800 1.0000 -.001   0.4800 1.0000 .000 .9800 1.0000 
A5 .001   0.5200 1.0000 .000 0.7400 1.0000 .001 .5100 1.0000 
* Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR). 
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Table 5: Longitudinal Targeted Variable Importance Estimates for HIV Infection Biomarkers 
 
 
Method 1: Regression with Autocorrelated 
Errors 
Method 2:Area Under LOESS Curve 
Estimation 
Biomarker 
EstimatedTime 
Slope Coefficient 
Unadjusted  
p-value 
p-value
 a
  Estimated 
Area under 
the LOESS 
Curve 
Unadjusted   
p-value 
p-value
 a
 
 
CD4 at baseline  0.0083 <.0001 <.0001 0.7817 <.0001 <.0001 
Plasma Viral Load 0.0001 0.9021 1.0000 0.0099 0.9490 1.0000 
CD8 Count  0.0042 0.1083 0.5994 0.3287 0.1381 0.7647 
CD4/CD8 T-cell 
Ratio  
0.0039 0.0811 0.5388 0.4362 0.0376 0.2497 
Lymphocyte count  0.0002 0.9126 1.0000 0.1213 0.5520 1.0000 
CD4 percent  -.0012 0.9144 1.0000 0.0731 0.9339 1.0000 
HIV subtype A -.0147 <.0001 <.0001 1.580 <.0001 <.0001 
HIV subtype C -.0133 0.1765 0.8374 1.139 0.3525 1.0000 
HIV subtype D 0.0109 <.0001 <.0001 0.9169 <.0001 <.0001 
Hemoglobin 0.0013 0.5066 1.0000 0.0053 0.9706 1.0000 
HSV-2 positive -.0092 <.0001 <.0001 0.8209 <.0001 <.0001 
Note: Results based on 5000 bootstrap samples. 
a Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR) procedure 
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Table 6: VIM as a Function of Time in Simulated Data 
 
 
Method 1: Regression with 
Autocorrelated Errors 
Method 2:Area Under LOESS Curve 
Estimation 
Number of time 
points 
p-value
 a
 p-value
 a
 
 
5 0.9448 0.3879 
10 0.2619 0.0042 
20 0.0003 <0.0001 
25 0.0002 <0.0001 
Note: Results based on 5000 bootstrap samples. 
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Table 7: Distribution of Stabilized Weights by Biomarker 
Biomarker  Mean (SD) Minimum - Maximum 
Baseline CD4 Cell count 1.000 (0.003) 0.966 - 1.029 
CD8 Cells Count 1.001 (0.060) 0.503 - 1.941 
CD4/CD8 T Cell Ratio 1.001 (0.026) 0.821 - 1.261 
CD4 Percentage 1.000 (0.008) 0.832 - 1.038 
Lymphocyte Count 0.997 (0.069) 0.493 - 1.929 
Plasma Viral Load  1.001 (0.032) 0.737 - 1.340 
Hemoglobin Level 1.003 (0.067) 0.521 - 2.236 
HSV-2 Status 1.006 (0.071) 0.696 - 1.535 
HIV Subtype A 1.040 (0.164) 0.329 - 3.372 
HIV Subtype C 1.015 (0.126) 0.409 - 3.179 
HIV Subtype D 1.028 (0.118) 0.425 - 2.781 
 Abbreviation: SD=Standard Deviation 
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Table 8: Overall survival Through 5 Years Post Estimated Infection Date 
 
Biomarker N n(%) 
5-year Cumulative probability of survival (%)  
and 2-sided 95% CI
 a
 
CD4 at baseline   500 cells/mm3 No 176 30(17.05) 84.86(79.11-90.62) 
Yes 126 82(65.08) 35.12(26.55-43.68) 
CD4 Percentage    20 % No 244 70(28.69) 72.05(66.08-78.03) 
Yes 58 42(72.41) 30.44(18.46-42.43) 
CD8 Count   1000 cells/mm3 No 210 75(35.71) 63.85(56.98-70.72) 
Yes 92 37(40.22) 64.09(54.07-74.11) 
Lymphocyte count < 1200  cells/mm
3
 No 250 79(31.60) 69.98(64.03-75.93) 
Yes 52 33(63.46) 34.83(21.25-48.40) 
CD4/CD8 Ratio   1 No 66 10(15.15) 87.71(79.08-96.34) 
Yes 236 102(43.22) 57.28(50.69-63.87) 
HIV RNA > 55000 copies/ml No 143 45(31.47) 69.37(61.59-77.15) 
Yes 79 37(46.84) 58.50(47.46-69.54) 
HIV Subtype A No 113 56(49.56) 53.18(43.73-62.63) 
Yes 76 20(26.32) 74.62(64.35-84.88) 
HIV Subtype C No 107 35(32.71) 67.26(57.71-76.80) 
Yes 82 41(50.00) 53.78(42.85-64.72) 
HIV Subtype D No 158 61(38.61) 63.62(55.89-71.35) 
Yes 31 15(48.39) 48.77(28.82-68.72) 
HSV-2 positive No 42 16(38.10) 60.12(44.78-75.47) 
Yes 96 49(51.04) 54.20(44.04-64.35) 
 
Hemoglobin Level < 11g/dl 
No 233 81(34.76) 66.21(59.88-72.54) 
Yes 69 31(44.93) 56.13(43.75-68.50) 
Abbreviations: N=number of subjects in category, n=number of subjects with event, CI=Confidence Intervals.                                                                                                               
ª Estimates based on the Kaplan-Meier method.                                                                                                                                                                                                               
Note: survival time for those with either two successive drops of <=350 cells/mm3 in CD4 cell counts or two drops of <=350 
cells/mm3 in CD4 cell counts within six months is defined as date of second drop minus estimated date of infection. 
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Table 9:  Estimates of Variable Importance Measures for Each Biomarker and Corresponding 95% 
Confidence Intervals from Standard Cox Proportional Hazards Model 
 
Biomarker 
Log Hazard Ratio 
Hazard Ratio 
(2-sided 95% CI) 
Unadjusted 
p-value 
p-value
 a
 
Baseline CD4 Cell count -0.763 0.466(0.379,0.573) <.0001 <.0001 
CD4/CD8 T cell Ratio -0.593 0.552(0.447,0.683) <.0001 <.0001 
Lymphocyte Count -0.351 0.704(0.586,0.846) 0.0002 0.0021 
Plasma Viral Load  0.349 1.417(1.171,1.715) 0.0003 0.0028 
Hemoglobin Level -0.156 0.855(0.736,0.994) 0.0408 0.2713 
HIV Subtype C 0.936 2.551(0.590,11.032) 0.2100 1.0000 
CD8 Cell Counts 0.072 1.075(0.909,1.272) 0.3998 1.0000 
HIV Subtype A -0.196 0.822(0.468,1.443) 0.4941 1.0000 
CD4 Percent -0.045 0.956(0.810,1.129) 0.5963 1.0000 
HIV Subtype D 0.102 1.107(0.620,1.979) 0.7303 1.0000 
HSV-2 Status -0.013 0.987(0.637,1.529) 0.9537 1.0000 
Abbreviation: CI=Confidence Intervals.                                                                                                                                                                                                                                                                                                            
a Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR) procedure. 
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Table 10:  Weighted Estimates of Variable Importance Measures for Each Biomarker and 
Corresponding 95% Confidence Intervals 
Biomarker 
Log Hazard Ratio 
Hazard Ratio  
(2-sided 95% CI) 
Unadjusted  
p-value 
p-value
 a
 
Baseline CD4 Cell count -0.674 0.510(0.418,0.621) <.0001 <.0001 
CD4/CD8 T- Cell Ratio -0.508 0.602(0.480,0.754) <.0001 0.0002 
Lymphocyte Count -0.297 0.743(0.640,0.862) <.0001 0.0010 
Plasma Viral Load  0.306 1.358(1.141,1.615) 0.0006 0.0046 
Hemoglobin Level -0.163 0.850(0.744,0.970) 0.0162 0.1073 
CD4 Percent -0.065 0.937(0.836,1.051) 0.2688 1.0000 
HIV Subtype D 0.184 1.202(0.720,2.006) 0.4815 1.0000 
CD8 Cell Counts 0.051 1.052(0.895,1.237) 0.5359 1.0000 
HIV Subtype A -0.111 0.895(0.608,1.317) 0.5739 1.0000 
HIV Subtype C 0.042 1.043(0.708,1.536) 0.8318 1.0000 
HSV-2 Status -0.013 0.987(0.638,1.527) 0.9542 1.0000 
Abbreviation: CI=Confidence Intervals.                                                                                                                                                                                                                                                                                                            
a Adjusted for multiplicity based on Benjamini & Yekutieli Dependent False Discovery Rate (FDR) procedure. 
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Figure 1: Plots of TVIM Data with Robust Smoother
For Biomarkers with a P-value <.05
VISIT
T
V
IM
-1.0
-0.5
0.0
0.5
0 10 20 30 40
CD4 Cell Count
0 10 20 30 40
HIV Subtype A
HIV Subtype D
-1.0
-0.5
0.0
0.5
HSV-2
147 
 
148 
 
 
